FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wolfgang Hiddemann

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Annika Dufour; Christian H Geisler; Debraj Guhathakurta; Wolfgang Hiddemann; Purvi M Kakadia; Sabine Lohmann; Gudrun Mellert; Marco Montillo; Giuseppe Palermo; Nancy Patten; Tadeusz Robak; Galina Salogub; Stephanie Schneider; Philippe Solal-Celigny; Karsten Spiekermann; Sim Truong; Martin Weisser; Lin Wu; Ru-Fang Yeh; Evelyn Zellmeier; Jan Braess; John Catalano; Anna Dmoszynska; David Dornan; Guillemette Duchateau-Nguyen; Tobias Benthaus; Stefan K Bohlander
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Harald Polzer; Diana Schmid; Wolfgang Hiddemann; Hanna Janke; Karsten Spiekermann
Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Felix S Lichtenegger; Frauke M Schnorfeil; Wolfgang Hiddemann; Marion Subklewe
Current strategies in immunotherapy for acute myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wolfgang Hiddemann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Annika Dufour; Christian H Geisler; Debraj Guhathakurta; Wolfgang Hiddemann; Purvi M Kakadia; Sabine Lohmann; Gudrun Mellert; Marco Montillo; Giuseppe Palermo; Nancy Patten; Tadeusz Robak; Galina Salogub; Stephanie Schneider; Philippe Solal-Celigny; Karsten Spiekermann; Sim Truong; Martin Weisser; Lin Wu; Ru-Fang Yeh; Evelyn Zellmeier; Jan Braess; John Catalano; Anna Dmoszynska; David Dornan; Guillemette Duchateau-Nguyen; Tobias Benthaus; Stefan K Bohlander
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Blood 2013;121(18):3650-7.
2013: Harald Polzer; Diana Schmid; Wolfgang Hiddemann; Hanna Janke; Karsten Spiekermann
Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Experimental hematology 2013;41(3):271-80.e4.
2013: Felix S Lichtenegger; Frauke M Schnorfeil; Wolfgang Hiddemann; Marion Subklewe
Current strategies in immunotherapy for acute myeloid leukemia.
Immunotherapy 2013;5(1):63-78.
2013: Eva Lengfelder; Carsten Müller-Tidow; Cristina Sauerland; Stephanie Schneider; Susanne Schnittger; Beate Schultheis; Hubert Serve; Karsten Spiekermann; Bernhard Wörmann; Carlo Aul; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Philipp Erben; Claudia Haferlach; Torsten Haferlach; Benjamin Hanfstein; Rüdiger Hehlmann; Achim Heinecke; Wolfgang Hiddemann; Wolf-Karsten Hofmann; Heinz A Horst; Karl-Anton Kreuzer; Utz Krug
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Annals of hematology 2013;92(1):41-52.
2012: Karoline Koch; German Ott; Andreas Rosenwald; Michael Unterhalt; Marianne Engelhard; Martin L Hansmann; Wolfgang Hiddemann; Eva Hoster; Wolfram Klapper
The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease.
Human pathology 2012;43(12):2274-81.
2012: Philipp A Greif; Tobias Herold; Wolfgang Hiddemann; Purvi M Kakadia; Nikola P Konstandin; Bianka Ksienzyk; Klaus Metzeler; Zlatana Pasalic; Maria Cristina Sauerland; Friederike Schneider; Stephanie Schneider; Karsten Spiekermann; Bernhard J Woermann; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Annika Dufour; Stefan K Bohlander
RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Haematologica 2012;97(12):1909-15.
2012: P Heussner; Wolfgang Hiddemann
[Psycho-oncology : the psyche and cancer].
Der Internist 2012;53(11):1296, 1298, 1300-1, 1303.
2012: Till M Seiler; Wolfgang Hiddemann
Advances in the management of follicular lymphoma.
Current opinion in oncology 2012;24(6):742-7.
2012: Eva C Winkler; Wolfgang Hiddemann; Georg Marckmann
Evaluating a patient's request for life-prolonging treatment: an ethical framework.
Journal of medical ethics 2012;38(11):647-51.
2012: Grit Hutter; M Rieken; A Rosenwald; Y Zimmermann; E Hartmann; Wolfgang Hiddemann; Martin Dreyling
Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.
Leukemia 2012;26(11):2442-4.
2012: Thomas Büchner; Hartmut Döhner; Konstanze Döhner; Gerhard Ehninger; Arnold Ganser; Joerg Hasford; Rüdiger Hehlmann; Gerhard Heil; Achim Heinecke; Wolfgang Hiddemann; Dieter Hoelzer; Verena S Hoffmann; Rainer Krahl; Michael Kramer; Jürgen Krauter; Utz Krug; Dietger W Niederwieser; Maria Cristina Sauerland; Markus Schaich; Richard F Schlenk; Sebastian Scholl; Daniela Späth; Wolfgang E Berdel; Markus Pfirrmann
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3604-10.
2012: Wolfgang Hiddemann
[Watch and wait in follicular lymphoma: time for change?].
Deutsche medizinische Wochenschrift (1946) 2012;137(42):2181-2.
2012: Martin Bornhäuser; Stefanie Buchholz; Andreas Burchert; Peter Dreger; Gerhard Ehninger; Herrmann Einsele; Ute Hegenbart; Wolfgang Hiddemann; Ernst Holler; Michael G Kiehl; Joachim Kienast; Nicolaus Kröger; Andreas Neubauer; Kerstin Schäfer-Eckart; Johannes Schetelig; Christoph Schmid; Rainer Schwerdtfeger; Michael Stadler; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Rudolf Trenschel; Matthias Stelljes
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
The lancet oncology 2012;13(10):1035-44.
2012: Klaus Metzeler; Vijay P S Rawat; Maria Cristina Sauerland; Richard F Schlenk; Karsten Spiekermann; Stefan K Bohlander; Jan Braess; Thomas Büchner; Lars Bullinger; Hartmut Döhner; Konstanze Döhner; Annika Dufour; Katrin E Edmaier; Michaela Feuring-Buske; Bernhard Heilmeier; Wolfgang Hiddemann; Christian Buske
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Blood 2012;120(10):2118-26.
2012: Philipp A Greif; Andreas Hauser; Tobias Herold; Wolfgang Hiddemann; Karl-Peter Hopfner; Eva Hoster; Purvi M Kakadia; Nikola P Konstandin; Stefan Krebs; Bianka Ksienzyk; Maria Cristina Sauerland; Friederike Schneider; Stephanie Schneider; Karsten Spiekermann; Martin Stanulla; Jutta Sturm; Belay Tizazu; Bernhard J Woermann; Marjan Yaghmaie; Evelyn Zellmeier; Tobias Benthaus; Wolfgang E Berdel; Helmut Blum; Jan Braess; Thomas Büchner; Petra Dörge; Annika Dufour; Alexander Graf; Stefan K Bohlander
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Blood 2012;120(2):395-403.
2012: Annika Dufour; Wolfgang Hiddemann; Eva Hoster; Purvi M Kakadia; Bianka Ksienzyk; Maria Cristina Sauerland; Friederike Schneider; Stephanie Schneider; Karsten Spiekermann; Marion Subklewe; Bernhard Wörmann; Tobias Benthaus; Wolfgang E Berdel; Stefan K Bohlander; Jan Braess; Thomas Büchner
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Annals of hematology 2012;91(7):1051-63.
2012: Grit Hutter; Alessandro Pastore; Malte Rieken; Oliver Weigert; Marc Weinkauf; Yvonne Zimmermann; Wolfgang Hiddemann; Martin Dreyling
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Annals of hematology 2012;91(6):847-56.
2012: Rüdiger Liersch; Bob Löwenberg; Carsten Müller-Tidow; Christoph Schliemann; Christian Schwöppe; Iris Appelmann; Michael Bayer; Wolfgang E Berdel; Christoph Biermann; Thomas Büchner; Joachim Gerss; Wolfgang Hiddemann; Torsten Kessler; Rolf M Mesters
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.
Blood 2012;119(22):5215-20.
2012: Friederike Schneider; Stephanie Schneider; Michael Unterhalt; Bernhard J Wörmann; Evelyn Zellmeier; Tobias Benthaus; Wolfgang E Berdel; Stefan K Bohlander; Jan Braess; Thomas Büchner; Christian Buske; Annika Dufour; Michaela Feuring-Buske; Achim Heinecke; Wolfgang Hiddemann; Eva Hoster; Purvi M Kakadia; Gudrun Mellert; Maria Cristina Sauerland; Karsten Spiekermann
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Blood 2012;119(19):4383-6.
2012: M Fiegl; Wolfgang Hiddemann
[Risk-adapted therapy in acute myeloid leukemia].
Der Internist 2012;53(4):392, 394-9.
2012: Felix S Lichtenegger; Katharina Mueller; Bettina Otte; Dolores J Schendel; Barbara Beck; Wolfgang Hiddemann; Marion Subklewe
CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.
PloS one 2012;7(9):e44266.
2011: D Hauke; Wolfgang Hiddemann; E Hoster; Stella Reiter-Theil; E C Winkler
The role of relatives in decisions concerning life-prolonging treatment in patients with end-stage malignant disorders: informants, advocates or surrogate decision-makers?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2667-74.
2011: A J Deshpande; H Döhner; K Döhner; P A Greif; Wolfgang Hiddemann; K Holzmann; Y Lin; S Opatz; L Quintanilla-Fend; Arefeh Rouhi; C Stadler; G Xu; Scott A Armstrong; N Arseni; S K Bohlander; Christian Buske
The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice.
Leukemia 2011;25(11):1718-27.
2011: T Herold; Wolfgang Hiddemann; V Jurinovic; P M Kakadia; U Mansmann; Klaus Metzeler; M Mulaw; Z Pasalic; M Schmidberger; M Schmidt; S Schneider; T Seiler; Karsten Spiekermann; S Thoene; A-L Boulesteix; Jan Braess; Christian Buske; A Dufour; Michaela Feuring-Buske; M Bergmann; Stefan K Bohlander
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
Leukemia 2011;25(10):1639-45.
2011: Tobias Herold; Vindi Jurinovic; Medhanie Mulaw; Till Seiler; Annika Dufour; Stephanie Schneider; Purvi M Kakadia; Michaela Feuring-Buske; Jan Braess; Karsten Spiekermann; Ulrich Mansmann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.
Genes, chromosomes & cancer 2011;50(7):546-58.
2011: Matthias Stelljes; Renate Arnold; Dietrich W Beelen; Wolfgang E Berdel; Bjorna Berning; Jan Braess; Thomas Büchner; Achim Heinecke; Wolfgang Hiddemann; Ernst Holler; Joachim Kienast; Hans J Kolb; Carsten Müller-Tidow; Maria Cristina Sauerland; Rainer Schwerdtfeger; Hubert Serve; Gerda Silling; Karsten Spiekermann
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Haematologica 2011;96(7):972-9.
2011: Christian Schmidt; Sebastian Fetscher; Christian Görg; Peter Kornek; Arnd Nusch; Thomas Kegel; Lenka Kellermann; Wolfgang Hiddemann; Guenter Fingerle-Rowson; Martin Dreyling
Treatment of indolent lymphoma in Germany - results of a representative population-based survey.
Clinical lymphoma, myeloma & leukemia 2011;11(2):204-11.
2011: Mi Kyung Jin; Eva Hoster; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Wolfram Klapper
Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.
Histopathology 2011;58(4):586-92.
2011: Katharina E Lechner; Tilmann Pohl; Lars Lindner; Bernhard Heilmeier; Til Seiler; Friederike Mumm; Johanna Tischer; Karsten Spiekermann; Wolfgang M Franz; Susanna Müller; Hans-Jochem Kolb; Wolfgang Hiddemann; Jan Braess
Acute heart failure: when standard therapy fails--an interdisciplinary challenge.
International journal of cardiology 2011;147(1):160-2.
2010: Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Lancet 2010;376(9757):2000-8.
2010: Vijay P S Rawat; Natalia Arseni; Farid Ahmed; Medhanie A Mulaw; Silvia Thoene; Bernhard Heilmeier; Tim Sadlon; Richard J D'Andrea; Wolfgang Hiddemann; Stefan K Bohlander; Christian Buske; Michaela Feuring-Buske
The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(39):16946-51.
2010: Rolf Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
The lancet oncology 2010;11(6):561-70.
2010: Annika Dufour; Friederike Schneider; Klaus Metzeler; Eva Hoster; Stephanie Schneider; Evelyn Zellmeier; Tobias Benthaus; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Jan Braess; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):570-7.
2010: Marcus Schlemmer; Clemens-Martin Wendtner; Lars H Lindner; Sultan Abdel-Rahman; Wolfgang Hiddemann; Rolf Issels
Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS).
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2010;26(2):127-35.
2009: Oliver Weigert; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Mantle cell lymphoma: state-of-the-art management and future perspective.
Leukemia & lymphoma 2009;50(12):1937-50.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2009: Till Seiler; Wolfgang Hiddemann; Martin Dreyling
Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Immunotherapy 2009;1(6):1015-24.
2009: Anagha Deshpande; Alessandro Pastore; Aniruddha J Deshpande; Yvonne Zimmermann; Grit Hutter; Marc Weinkauf; Christian Buske; Wolfgang Hiddemann; Martin Dreyling
3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Cell cycle (Georgetown, Tex.) 2009;8(21):3584-92.
2009: Klaus Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5031-8.
2009: Till Seiler; Wolfgang Hiddemann
Microenvironmental influences and antigenic stimulation in chronic lymphocytic leukemia.
Onkologie 2009;32(10):550-1.
2009: Grit Hutter; M Scheubner; G Ott; Y Zimmermann; K Hübler; S Roth; S Stilgenbauer; Jörg Kalla; H Stöcklein; Wolfgang Hiddemann; Martin Dreyling
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation.
Annals of hematology 2009;88(9):821-8.
2009: Wolfram Klapper; Philip M Kluin; Roman Kodet; Yuri A Krivolapov; Christoph Loddenkemper; Peter Möller; Konrad Müller-Hermelink; Ilske Oschlies; German Ott; Stefano Pileri; Elisabeth Ralfkiaer; Andreas Rosenwald; Grzegorz Rymkiewicz; Harald Stein; Michael Unterhalt; Jeroen van der Laak; Johan H van Krieken; Hans Heinrich Wacker; Thomas E F Barth; Françoise Berger; Heinz-Wolfram Bernd; José Cabeçadas; Elias Campo; Sergio B Cogliatti; Olaf Determann; Martin Dreyling; Martin-Leo Hansmann; Wolfgang Hiddemann; Eva Hoster
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network.
Journal of hematopathology 2009;2(2):103-11.
2009: Roland Reibke; A Hausmann; J Cnossen; Wolfgang Hiddemann; Karsten Spiekermann; Jan Braess
[Severe microcytic anemia with megaloblastic changes in the bone marrow. A hematological paradoxon?].
Der Internist 2009;50(7):881-6.
2009: Klaus Metzeler; Stefan Boeck; Birgit Christ; Andreas Hausmann; Hans-Joachim Stemmler; Klaus G Parhofer; Helmut Ostermann; Wolfgang Hiddemann; Jan Braess
Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.
Leukemia research 2009;33(7):e69-72.
2009: B Heilmeier; Karsten Spiekermann; S Bohlander; Christian Buske; Michaela Feuring-Buske; S Schneider; Wolfgang Hiddemann; J Braess
[Modern leukemia diagnosis in adults].
Deutsche medizinische Wochenschrift (1946) 2009;134(23):1222-6.
2009: Friederike Schneider; Eva Hoster; Michael Unterhalt; Stephanie Schneider; Annika Dufour; Tobias Benthaus; Gudrun Mellert; Evelin Zellmeier; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske; Jan Braess; Susanne Fritsch; Achim Heinecke; Maria C Sauerland; Wolfgang E Berdel; Thomas Buechner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Blood 2009;113(21):5250-3.
2009: Oliver Weigert; Eckhart Weidmann; Rudolf Mueck; Martin Bentz; Christoph von Schilling; Robert Rohrberg; Kathleen Jentsch-Ullrich; Wolfgang Hiddemann; Martin Dreyling
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Leukemia & lymphoma 2009;50(5):716-22.
2009: Eva C Winkler; Stella Reiter-Theil; Dorothee Lange-Riess; Nina Schmahl-Menges; Wolfgang Hiddemann
Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2225-30.
2009: Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood 2009;113(17):3903-10.
2009: Carola Reindl; Hilmar Quentmeier; Konstantin Petropoulos; Philipp A Greif; Tobias Benthaus; Bob Argiropoulos; Gudrun Mellert; Sridhar Vempati; Justus Duyster; Christian Buske; Stefan K Bohlander; Keith R Humphries; Wolfgang Hiddemann; Karsten Spiekermann
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2238-47.
2009: S Thoene; V P S Rawat; B Heilmeier; E Hoster; Klaus Metzeler; T Herold; Wolfgang Hiddemann; N Gökbuget; D Hoelzer; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
Leukemia 2009;23(4):649-55.
2009: Sebastian Stintzing; Volker Heinemann; Nicolas Moosmann; Wolfgang Hiddemann; Andreas Jung; Thomas Kirchner
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
Deutsches Ärzteblatt international 2009;106(12):202-6.
2009: Marc Weinkauf; Yvonne Zimmermann; Elena Hartmann; Andreas Rosenwald; Malte Rieken; Alessandro Pastore; Grit Hutter; Wolfgang Hiddemann; Martin Dreyling
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Electrophoresis 2009;30(6):974-86.
2009: Annina Herrmann; Eva Hoster; Thomas Zwingers; Günter Brittinger; Marianne Engelhard; Peter Meusers; Marcel Reiser; Roswitha Forstpointner; Bernd Metzner; Norma Peter; Bernhard Wörmann; Lorenz Trümper; Michael Pfreundschuh; Hermann Einsele; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Improvement of overall survival in advanced stage mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):511-8.
2009: Christina Papadaki; Annika Dufour; Marlene Seibl; Stephanie Schneider; Stefan K Bohlander; Evelyn Zellmeier; Gudrun Mellert; Wolfgang Hiddemann; Karsten Spiekermann
Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
British journal of haematology 2009;144(4):517-23.
2009: Martin Dreyling; Wolfgang Hiddemann
Current treatment standards and emerging strategies in mantle cell lymphoma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():542-51.
2009: Valeria Milani; Stefan Stangl; Rolf Issels; Mathias Gehrmann; Beate Wagner; Kathrin Hube; Doris Mayr; Wolfgang Hiddemann; Michael Molls; Gabriele Multhoff
Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
Journal of translational medicine 2009;7():50.
2009: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2009: Christian Buske; Eva Hoster; Martin Dreyling; Hartmut Eimermacher; Hannes Wandt; Bernd Metzner; R Fuchs; J Bittenbring; B Woermann; K Hohloch; G Hess; Wolf-Dieter Ludwig; J Schimke; S Schmitz; Michael Kneba; Maximilian Reiser; U Graeven; Wolfram Klapper; Michael Unterhalt; Wolfgang Hiddemann
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Leukemia 2009;23(1):153-61.
2008: Klaus Metzeler; Manuela Hummel; Clara D Bloomfield; Karsten Spiekermann; Jan Braess; Maria-Cristina Sauerland; Achim Heinecke; Michael Radmacher; Guido Marcucci; Susan P Whitman; Kati Maharry; Peter Paschka; Richard A Larson; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Wolfgang Hiddemann; Stefan K Bohlander; Christian Buske
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Blood 2008;112(10):4193-201.
2008: Lars H Lindner; H Ostermann; Wolfgang Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
International journal of hematology 2008;88(4):381-6.
2008: Tobias Benthaus; Friederike Schneider; Gudrun Mellert; Evelyn Zellmeier; Stephanie Schneider; Purvi M Kakadia; Wolfgang Hiddemann; Stefan K Bohlander; Michaela Feuring-Buske; Jan Braess; Karsten Spiekermann; Annika Dufour
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
British journal of haematology 2008;143(2):230-9.
2008: Martin Dreyling; Wolfgang Hiddemann
Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Current opinion in oncology 2008;20(5):487-94.
2008: Sridhar Vempati; Carola Reindl; Ulla Wolf; Ruth Kern; Konstantin Petropoulos; Vegi M Naidu; Christian Buske; Wolfgang Hiddemann; Tobias M Kohl; Karsten Spiekermann
Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4437-45.
2008: Michael Fiegl; Lars H Lindner; Matthias Juergens; Hansjoerg Eibl; Wolfgang Hiddemann; Jan Braess
Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.
Cancer chemotherapy and pharmacology 2008;62(2):321-9.
2008: Martin Dreyling; Oliver Weigert; Wolfgang Hiddemann
Current treatment standards and future strategies in mantle cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 4():iv41-4.
2008: Sebastian Böttcher; Matthias Ritgen; Sebastian Buske; Stefan Gesk; Wolfram Klapper; Eva Hoster; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling; Reiner Siebert; Michael Kneba; Christiane Pott
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Haematologica 2008;93(4):551-9.
2008: D Bararia; Arun Trivedi; Abdul Ali Peer Zada; P A Greif; M A Mulaw; M Christopeit; Wolfgang Hiddemann; Stefan K Bohlander; Gerhard Behre
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha.
Leukemia 2008;22(4):800-7.
2008: Christoph Schmid; Michael Schleuning; Marcus Hentrich; G E Markl; Armin Gerbitz; Johanna Tischer; Georg Ledderose; D Oruzio; Wolfgang Hiddemann; Hans-Jochem Kolb
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Bone marrow transplantation 2008;41(8):721-7.
2008: Konstantin Petropoulos; Natalia Arseni; Christina Schessl; Christiane R Stadler; Vijay P S Rawat; Aniruddha J Deshpande; Bernhard Heilmeier; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis.
The Journal of experimental medicine 2008;205(3):515-22.
2008: Farid Ahmed; Natalia Arseni; Hanno Glimm; Wolfgang Hiddemann; Christian Buske; Michaela Feuring-Buske
Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors.
Stem cells (Dayton, Ohio) 2008;26(3):810-8.
2008: Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
Blood 2008;111(4):2385-7.
2008: Lars H Lindner; Martin Hossann; Michael Vogeser; Nicole Teichert; Kirsten Wachholz; Hansjörg Eibl; Wolfgang Hiddemann; Rolf Issels
Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
Journal of controlled release : official journal of the Controlled Release Society 2008;125(2):112-20.
2008: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel Van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Blood 2008;111(2):558-65.
2008: Vijay P S Rawat; Silvia Thoene; Vegi M Naidu; Natalia Arseni; Bernhard Heilmeier; Klaus Metzeler; Konstantin Petropoulos; Aniruddha Deshpande; Leticia Quintanilla-Martinez; Stefan K Bohlander; Karsten Spiekermann; Wolfgang Hiddemann; Michaela Feuring-Buske; Christian Buske
Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia.
Blood 2008;111(1):309-19.
2008: Michael Fiegl; Inka Zimmermann; Isolde Lorenz; Wolfgang Hiddemann; Jan Braess
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
Annals of hematology 2008;87(1):27-33.
2007: Marc Weinkauf; Maximilian Christopeit; Wolfgang Hiddemann; Martin Dreyling
Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.
Electrophoresis 2007;28(23):4416-26.
2007: Christian Buske; Wolfgang Hiddemann
[The older patient with malignant diseases].
Der Internist 2007;48(11):1206,1208-10.
2007: F Schneider; Stefan K Bohlander; S Schneider; C Papadaki; P Kakadyia; A Dufour; Sridhar Vempati; Michael Unterhalt; Michaela Feuring-Buske; Christian Buske; Jan Braess; Hannes Wandt; Wolfgang Hiddemann; Karsten Spiekermann
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Leukemia 2007;21(10):2199-201.
2007: Thomas Büchner; Utz Krug; Wolfgang E Berdel; Achim Heinecke; Maria Cristina Sauerland; Bernhard Wörmann; Wolfgang Hiddemann
Maintenance for acute myeloid leukemia revisited.
Current treatment options in oncology 2007;8(4):296-304.
2007: Wolfram Klapper; Eva Hoster; Lars Rölver; Carsten Schrader; Dirk Janssen; Markus Tiemann; Heinz-Wolfram Bernd; Olaf Determann; Martin-Leo Hansmann; Peter Möller; Alfred Feller; Harald Stein; Hans-Heinrich Wacker; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; German Ott
Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3330-6.
2007: Tobias M Kohl; C Hellinger; Farid Ahmed; Christian Buske; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Leukemia 2007;21(8):1763-72.
2007: Sridhar Vempati; Carola Reindl; Seshu Kumar Kaza; Ruth Kern; Theodora Malamoussi; Martin Dugas; Gudrun Mellert; Susanne Schnittger; Wolfgang Hiddemann; Karsten Spiekermann
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.
Blood 2007;110(2):686-94.
2007: Rudolf Weide; Georg Hess; Hubert Köppler; Jochen Heymanns; Jörg Thomalla; Ali Aldaoud; Christoph Losem; Stefan Schmitz; Ursula Haak; Christoph Huber; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Leukemia & lymphoma 2007;48(7):1299-306.
2007: Wolfgang Hiddemann
[High performance medicine and humanism. A contradiction?].
Der Internist 2007;48 Suppl 1():S17-9.
2007: Martin Weisser; Claudia Haferlach; Wolfgang Hiddemann; Susanne Schnittger
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
Leukemia 2007;21(6):1177-82.
2007: Wolfgang Hiddemann
[High-performance medicine and humanitarian principles].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(5):331-5.
2007: Susanne Fritsch; Christian Buske; Bernhard Wörmann; Ulrich Wedding; Wolfgang Hiddemann; Karsten Spiekermann
[Therapy of acute myeloid leukemia (AML) for medically non-fit patients].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):324-9.
2007: Michael Fiegl; Wolfgang Hiddemann; Jan Braess
[Current therapeutic strategies in the management of acute myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):309-16.
2007: Bernhard Heilmeier; Christian Buske; Karsten Spiekermann; Stefan K Bohlander; Michaela Feuring-Buske; Wolfgang Hiddemann; Jan Braess
[Diagnostics, classification and prognostic criteria of acute myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):296-308.
2007: Oliver Christ; Michaela Feuring-Buske; Wolfgang Hiddemann; Christian Buske
[Pathobiology of acute myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):290-5.
2007: F Schneider; Jan Braess; Michaela Feuring-Buske; Wolfgang Hiddemann; Karsten Spiekermann
[Elevated Hemoglobin--polyglobulia or polycythemia?].
MMW Fortschritte der Medizin 2007;149(15):40-1, 43.
2007: Klaus Metzeler; Jan Braess; Karsten Spiekermann; Stefan K Bohlander; Wolfgang Hiddemann; Christian Buske; Michaela Feuring-Buske
[Fortuitous finding: thrombocytopenia and thrombocytosis].
MMW Fortschritte der Medizin 2007;149(15):34-5, 37.
2007: Christian Buske; Wolfgang Hiddemann
[Malignant lymphoma--there are still many open questions].
Der Internist 2007;48(4):349-50.
2007: Martin Dreyling; Michael Unterhalt; Oliver Weigert; Wolfgang Hiddemann
[Therapy of mantle cell lymphoma].
Der Internist 2007;48(4):382-8.
2007: Michael Fiegl; Matthias Juergens; Wolfgang Hiddemann; Jan Braess
Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.
Leukemia research 2007;31(4):531-9.
2007: Arun Trivedi; D Bararia; Maximilian Christopeit; A A Peerzada; Sheo M Singh; Arnd Kieser; Wolfgang Hiddemann; HM Behre; Gerhard Behre
Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination.
Oncogene 2007;26(12):1789-801.
2007: Oliver Weigert; A Pastore; M Rieken; N Lang; Wolfgang Hiddemann; Martin Dreyling
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Leukemia 2007;21(3):524-8.
2007: Oliver Weigert; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Current management of mantle cell lymphoma.
Drugs 2007;67(12):1689-702.
2007: Wolfgang Hiddemann; Christian Buske; Martin Dreyling; Oliver Weigert; Georg Lenz; Michael Unterhalt
Current management of follicular lymphomas.
British journal of haematology 2007;136(2):191-202.
2007: Christina Nickenig; Martin Dreyling; Eva Hoster; W-D Ludwig; Bernd Dörken; Mathias Freund; C Huber; Arnold Ganser; Lorenz Trümper; Roswitha Forstpointner; Michael Unterhalt; Wolfgang Hiddemann
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):136-42.
2006: Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Blood 2006;108(13):4003-8.
2006: Martin Weisser; Wolfgang Kern; Claudia Schoch; Claudia Tschulik; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
Leukemia & lymphoma 2006;47(12):2645-7.
2006: Marc Wittmann; Tanja Vollmer; Claudia Schweiger; Wolfgang Hiddemann
The relation between the experience of time and psychological distress in patients with hematological malignancies.
Palliative & supportive care 2006;4(4):357-63.
2006: Abdul Ali Peer Zada; John A Pulikkan; D Bararia; Mulu Geletu; Arun Trivedi; Mumtaz Y Balkhi; Wolfgang Hiddemann; Daniel G Tenen; HM Behre; Gerhard Behre
Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.
Leukemia 2006;20(12):2137-46.
2006: Aniruddha J Deshpande; Monica Cusan; Vijay P S Rawat; Hendrik Reuter; Alexandre Krause; Christiane Pott; Leticia Quintanilla-Martinez; Purvi Kakadia; Florian Kuchenbauer; Farid Ahmed; Eric Delabesse; Meinhard Hahn; Peter Lichter; Michael Kneba; Wolfgang Hiddemann; Elizabeth Macintyre; Cristina Mecucci; Wolf-Dieter Ludwig; R Keith Humphries; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia.
Cancer cell 2006;10(5):363-74.
2006: Marc Weinkauf; Wolfgang Hiddemann; Martin Dreyling
Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background.
Electrophoresis 2006;27(22):4555-8.
2006: Wolfgang Hiddemann
["We need new alliances." Interview by Hildegrad Kaulen].
Deutsche medizinische Wochenschrift (1946) 2006;Suppl 1():8-9.
2006: Susanne Fritsch; Klaus Metzeler; Wolfgang Hiddemann; Christian Buske
[Diagnostics and therapy of acute myeloid leukemia].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2401-6.
2006: Wolfgang Hiddemann; Michael Unterhalt
Current treatment strategies in follicular lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x155-9.
2006: Florian Kuchenbauer; Susanne Schnittger; Thomas Look; G Gilliland; D Tenen; Torsten Haferlach; Wolfgang Hiddemann; Christian Buske; Claudia Schoch
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
British journal of haematology 2006;134(6):616-9.
2006: Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Christian Buske
Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
Current oncology reports 2006;8(5):368-75.
2006: Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Trumper; Marcel Reiser; Hannes Wandt; Eva Lengfelder; Michael Unterhalt; Wolfgang Hiddemann
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Cancer 2006;107(5):1014-22.
2006: Christian Buske; Eva Hoster; Martin Dreyling; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Blood 2006;108(5):1504-8.
2006: Oliver Weigert; Timothy M Illidge; Wolfgang Hiddemann; Martin Dreyling
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Cancer 2006;107(4):686-95.
2006: Christoph Schmid; Michael Schleuning; Rainer Schwerdtfeger; Bernd Hertenstein; Eva Mischak-Weissinger; Donald Bunjes; Stephanie von Harsdorf; Christoph Scheid; Udo Holtick; Hildegard Greinix; Felix Keil; Barbara Schneider; Michael Sandherr; Gesine Bug; Johanna Tischer; Georg Ledderose; Michael Hallek; Wolfgang Hiddemann; Hans-Jochem Kolb
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Blood 2006;108(3):1092-9.
2006: Klaus Metzeler; Susanne Fritsch; Christian Buske; Wolfgang Hiddemann
[Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment].
Deutsche medizinische Wochenschrift (1946) 2006;131(25-26):1466-8.
2006: Xaver Schiel; H Link; Georg Maschmeyer; Bertram Glaß; Oliver A Cornely; Dieter Buchheidt; M Wilhelm; Gerda Silling; M Helmerking; Wolfgang Hiddemann; Helmut Ostermann; Marcus Hentrich
A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.
Infection 2006;34(3):118-26.
2006: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Brunangelo Falini; Niccolò Bolli; Jing Shan; Maria Paola Martelli; Arcangelo Liso; Alessandra Pucciarini; Barbara Bigerna; Laura Pasqualucci; Roberta Mannucci; Roberto Rosati; Paolo Gorello; Daniela Diverio; Giovanni Roti; Enrico Tiacci; Giovanni Cazzaniga; Andrea Biondi; Suzanne Schnittger; Torsten Haferlach; Wolfgang Hiddemann; Massimo F Martelli; Wei Gu; Cristina Mecucci; Ildo Nicoletti
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
Blood 2006;107(11):4514-23.
2006: Michaela Feuring-Buske; Wolfgang Hiddemann
[Stem cell therapy].
Der Internist 2006;47(5):457-8.
2006: Marcus Hentrich; Karl Fehnle; Helmut Ostermann; Joachim Kienast; Oliver A Cornely; Christoph Salat; Ralf Ubelacker; Dieter Buchheidt; Gerhard Behre; Wolfgang Hiddemann; Xaver Schiel
IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial.
Critical care medicine 2006;34(5):1319-25.
2006: Carola Reindl; Ksenia Bagrintseva; Sridhar Vempati; Susanne Schnittger; Joachim W Ellwart; Katja Wenig; Karl-Peter Hopfner; Wolfgang Hiddemann; Karsten Spiekermann
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Blood 2006;107(9):3700-7.
2006: Susanne Schnittger; Tobias M Kohl; Nina Leopold; Claudia Schoch; H-Erich Wichmann; Wolfgang Kern; Peter Lohse; Wolfgang Hiddemann; Torsten Haferlach; Karsten Spiekermann
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
Genes, chromosomes & cancer 2006;45(4):332-7.
2006: Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Blood 2006;107(6):2271-8.
2006: Christian Buske; Wolfgang Hiddemann
Rituximab maintenance therapy in indolent NHL: a clinical review.
Leukemia research 2006;30 Suppl 1():S11-5.
2006: Wolfgang Hiddemann
Rituximab maintenance therapy in follicular lymphoma comes of age.
Leukemia research 2006;30 Suppl 1():S1-2.
2006: Susanne Schnittger; Tobias M Kohl; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Karsten Spiekermann; Claudia Schoch
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Blood 2006;107(5):1791-9.
2006: Hanna S Radomska; Daniela S Bassères; Rui Zheng; Pu Zhang; Tajhal Dayaram; Yukiya Yamamoto; David W Sternberg; Nathalie A Lokker; Neill A Giese; Stefan K Bohlander; Susanne Schnittger; Marie-Hélène Delmotte; Roger J Davis; Donald Small; Wolfgang Hiddemann; D Gary Gilliland; Daniel G Tenen
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
The Journal of experimental medicine 2006;203(2):371-81.
2006: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Cancer 2006;106(4):839-47.
2006: Grit Hutter; Miriam Scheubner; Yvonne Zimmermann; Jörg Kalla; Tiemo Katzenberger; Karin Hübler; Sabine Roth; Wolfgang Hiddemann; German Ott; Martin Dreyling
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Genes, chromosomes & cancer 2006;45(2):203-10.
2006: Marcus Schlemmer; Clemens-Martin Wendtner; Martin Falk; Sultan Abdel-Rahman; Thomas Licht; Jens Baumert; Christian Straka; Marcus Hentrich; Christoph Salat; Wolfgang Hiddemann; Rolf Issels
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Oncology 2006;71(1-2):32-9.
2006: Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Classification of AML by DNA-oligonucleotide microarrays.
Methods in molecular medicine 2006;125():213-40.
2006: Christian Buske; Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
Current status and perspective of antibody therapy in follicular lymphoma.
Haematologica 2006;91(1):104-12.
2005: Florian Kuchenbauer; Wolfgang Kern; Claudia Schoch; Alexander Kohlmann; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Haematologica 2005;90(12):1617-25.
2005: Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood 2005;106(12):3725-32.
2005: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Blood 2005;106(12):3733-9.
2005: Natalia Arseni; Farid Ahmed; Wolfgang Hiddemann; Christian Buske; Michaela Feuring-Buske
Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
Haematologica 2005;90(11):1577-8.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Claudia Schoch
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Haematologica 2005;90(11):1502-10.
2005: Thomas Büchner; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Carlo Aul; Eva Lengfelder; Andrea Schumacher; Albrecht Reichle; Peter Staib; Leopold Balleisen; Hartmut Eimermacher; Andreas Grüneisen; Herbert Rasche; Maria Cristina Sauerland; Achim Heinecke; Rolf M Mesters; Hubert Serve; Joachim Kienast; Wolfgang Hiddemann
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Wolfgang Hiddemann; Karsten Spiekermann; Christian Buske; Michaela Feuring-Buske; Jan Braess; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang E Berdel; Bernhard Wörmann; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Annals of hematology 2005;84(12):785-91.
2005: Jan Braess; Michael Fiegl; Isolde Lorenz; Karin Waxenberger; Wolfgang Hiddemann
Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7415-25.
2005: Markus Tiemann; Carsten Schrader; Wolfram Klapper; Martin Dreyling; Elias Campo; Andrew Norton; Francoise Berger; Philip M Kluin; German Ott; Stephano Pileri; Ennio Pedrinis; Alfred C Feller; Hartmut Merz; Dirk Janssen; Martin-Leo Hansmann; Han Krieken; Peter Möller; Harald Stein; Michael Unterhalt; Wolfgang Hiddemann; Reza Parwaresch
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.
British journal of haematology 2005;131(1):29-38.
2005: Martin Dreyling; Christian Buske; Wolfgang Hiddemann
[Up-to-date treatment of follicular lymphomas].
Deutsche medizinische Wochenschrift (1946) 2005;130(38):2149-54.
2005: Wolfgang Hiddemann; Christian Buske; Martin Dreyling; Oliver Weigert; Georg Lenz; Roswitha Forstpointner; Christina Nickenig; Michael Unterhalt
Treatment strategies in follicular lymphomas: current status and future perspectives.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6394-9.
2005: Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Claudia Schoch
Global approach to the diagnosis of leukemia using gene expression profiling.
Blood 2005;106(4):1189-98.
2005: Wolfgang Hiddemann; Volker Heinemann
[Current progress in therapy of malignant diseases].
Deutsche medizinische Wochenschrift (1946) 2005;130(31-32):1837-40.
2005: Rudolf Arnold; Anja Rinke; Klaus Jochen Klose; Hans-Helge Müller; Matthias U Wied; Karin Zamzow; Christina Schmidt; Carmen Schade-Brittinger; Peter Barth; Roland Moll; Michael Koller; Michael Unterhalt; Wolfgang Hiddemann; Martin Schmidt-Lauber; Marianne Pavel; Christian N Arnold
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005;3(8):761-71.
2005: Michael Hölzel; Michaela Rohrmoser; Martin Schlee; Thomas Grimm; Thomas Harasim; Anastassia Malamoussi; Anita Gruber-Eber; Elisabeth Kremmer; Wolfgang Hiddemann; Georg W Bornkamm; Dirk Eick
Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation.
The Journal of cell biology 2005;170(3):367-78.
2005: Christina Schessl; Vijay P S Rawat; Monica Cusan; Aniruddha Deshpande; Tobias M Kohl; Patricia M Rosten; Karsten Spiekermann; R Keith Humphries; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
The Journal of clinical investigation 2005;115(8):2159-68.
2005: Karsten Spiekermann; Wolfgang Hiddemann
[Molecular target structures in oncology].
Der Internist 2005;46(8):847-8, 850-4, 856-60.
2005: Martin Weisser; Wolfgang Kern; S Rauhut; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Leukemia 2005;19(8):1416-23.
2005: Florian Kuchenbauer; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
British journal of haematology 2005;130(2):196-202.
2005: Martin Weisser; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
Haematologica 2005;90(7):881-9.
2005: Christian Buske; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
Transplantation strategies for patients with follicular lymphoma.
Current opinion in hematology 2005;12(4):266-72.
2005: Claudia Schoch; Alexander Kohlmann; Martin Dugas; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
Leukemia 2005;19(7):1224-8.
2005: Claudia Schoch; Wolfgang Kern; Alexander Kohlmann; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
Genes, chromosomes & cancer 2005;43(3):227-38.
2005: Alexander Kohlmann; Claudia Schoch; Martin Dugas; Susanne Schnittger; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.
Leukemia 2005;19(6):953-64.
2005: Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Claudia Schoch
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.
Genes, chromosomes & cancer 2005;43(2):113-27.
2005: Gerhard Herzog; Juxian Lu-Hesselmann; Yvonne Zimmermann; Torsten Haferlach; Wolfgang Hiddemann; Martin Dreyling
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events.
Haematologica 2005;90(5):693-5.
2005: Ksenia Bagrintseva; Stefanie Geisenhof; Ruth Kern; Sabine Eichenlaub; Carola Reindl; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Blood 2005;105(9):3679-85.
2005: Karsten Spiekermann; Wolfgang Hiddemann; Susanne Schnittger
[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Deutsche medizinische Wochenschrift (1946) 2005;130(16):1020-5.
2005: Tobias M Kohl; Susanne Schnittger; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
Blood 2005;105(8):3319-21.
2005: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Claudia Schoch
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Haematologica 2005;90(4):558-9.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Annals of hematology 2005;84(4):250-7.
2005: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Blood 2005;105(7):2677-84.
2005: Michael Fiegl; Thomas Büchner; Wolfgang Hiddemann; Jan Braess
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Annals of hematology 2005;84(4):227-31.
2005: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1984-92.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Leukemia & lymphoma 2005;46(3):357-66.
2005: Kai Neben; Susanne Schnittger; Benedikt Brors; Björn Tews; Felix Kokocinski; Torsten Haferlach; Jasmin Müller; Meinhard Hahn; Wolfgang Hiddemann; Roland Eils; Peter Lichter; Claudia Schoch
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Oncogene 2005;24(9):1580-8.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Cancer genetics and cytogenetics 2005;157(1):53-61.
2005: Christian Buske; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
[Monoclonal antibody therapy for malignant lymphoma].
Medizinische Klinik (Munich, Germany : 1983) 2005;100(1):14-24.
2005: Thomas Buechner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Bernhard Woermann; Wolfgang Hiddemann
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2005: Martin Dreyling; Christian Buske; Wolfgang Hiddemann
Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii99-104.
2005: Marcus Hentrich; Daniel Oruzio; Gabriele Jäger; Marcus Schlemmer; Michael Schleuning; Xaver Schiel; Wolfgang Hiddemann; Hans-Jochem Kolb
Impact of human herpesvirus-6 after haematopoietic stem cell transplantation.
British journal of haematology 2005;128(1):66-72.
2005: M Krych; Wolfgang Hiddemann
[Oncological emergencies].
Der Internist 2005;46(1):7-8.
2004: Georg Lenz; Martin Dreyling; Eva Schiegnitz; Torsten Haferlach; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4926-33.
2004: Christian Buske; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
[Monoclonal antibody treatment of malignant lymphoma].
Der Internist 2004;45(12):1370-7.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood 2004;104(10):3078-85.
2004: Roswitha Forstpointner; Martin Dreyling; Roland Repp; Sandra Hermann; Annette Hänel; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Robert Rohrberg; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood 2004;104(10):3064-71.
2004: Georg Lenz; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
[Current strategies in the treatment of advanced stage mantle cell lymphoma].
Deutsche medizinische Wochenschrift (1946) 2004;129(45):2429-33.
2004: Mirjam Klaus; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Claudia Schoch
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Cancer genetics and cytogenetics 2004;155(1):47-56.
2004: Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry. Part B, Clinical cytometry 2004;62(1):25-38.
2004: Georg Lenz; Martin Dreyling; Eva Schiegnitz; Roswitha Forstpointner; Hannes Wandt; Mathias Freund; Georg Hess; Lorenz Truemper; Volker Diehl; Martin Kropff; Michael Kneba; Norbert Schmitz; Bernd Metzner; Markus Pfirrmann; Michael Unterhalt; Wolfgang Hiddemann
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Blood 2004;104(9):2667-74.
2004: Florian Kuchenbauer; Christian P Strassburg; Arndt Vogel; Wolfgang Hiddemann; Ulrich Beuers
UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer.
Hepatology (Baltimore, Md.) 2004;40(4):1021.
2004: Georg Lenz; Grit Hutter; Wolfgang Hiddemann; Martin Dreyling
Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.
Annals of hematology 2004;83(10):628-33.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Thomas Büchner; Wolfgang Hiddemann; Torsten Haferlach
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Haematologica 2004;89(9):1082-90.
2004: Georg Lenz; Wolfgang Hiddemann; Martin Dreyling
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Cancer 2004;101(5):883-93.
2004: Jan Braess; Peter Schneiderat; Claudia Schoch; Michael Fiegl; Isolde Lorenz; Wolfgang Hiddemann
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.
British journal of haematology 2004;126(3):338-47.
2004: Matthäus Krych; Martin Dreyling; Michael Kneba; D Hoelzer; Wolfgang Hiddemann; Michael Hallek
[Prophylaxis and differential therapy of tumorlysis syndrome].
Deutsche medizinische Wochenschrift (1946) 2004;129(25-26):1440-5.
2004: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2510-1.
2004: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Annals of hematology 2004;83(6):349-55.
2004: Thomas Büchner; Wolfgang E Berdel; Wolfgang Hiddemann
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
The New England journal of medicine 2004;350(21):2215-6.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica 2004;89(5):528-40.
2004: Torsten Haferlach; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Ksenia Bagrintseva; Ruth Schwab; Tobias M Kohl; Susanne Schnittger; Sabine Eichenlaub; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Blood 2004;103(6):2266-75.
2004: Georg Lenz; Martin Dreyling; Wolfgang Hiddemann
Mantle cell lymphoma: established therapeutic options and future directions.
Annals of hematology 2004;83(2):71-7.
2004: Vijay P S Rawat; Monica Cusan; Aniruddha Deshpande; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; R Keith Humphries; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(3):817-22.
2004: Wolfgang Kern; Daniela Voskova; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(5):410-8.
2004: Wolfgang Kern; Alexander Kohlmann; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(4):225-37.
2004: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Acta haematologica 2004;112(1-2):68-78.
2004: Joachim Kienast; Matthias Stelljes; Bjorna Berning; Matthias Kröger; Maria Cristina Sauerland; Achim Heinecke; Claudia Schoch; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel
Transplantation strategies in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S136-7.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Christian Buske; H Dreyling; Michael Unterhalt; Wolfgang Hiddemann
Novel treatment strategies in follicular lymphoma.
Annals of hematology 2004;83 Suppl 1():S72.
2004: Wolfgang Hiddemann; Wolfgang Kern; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG.
Annals of hematology 2004;83 Suppl 1():S53-4.
2004: W Kern; Torsten Haferlach; Claudia Schoch; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2004: Grit Hutter; Christina Nickenig; Henk Garritsen; Frank Hellenkamp; Andre Hoerning; Wolfgang Hiddemann; Martin Dreyling
Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell lines.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):61-8.
2004: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Leukemia 2004;18(1):63-71.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Leukemia 2004;18(1):120-5.
2003: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles Alan Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo Coco; Rein Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Ulrich T Hacker; Georg Lenz; Gerd Brehm; Josef Müller-Höcker; Andreas Schalhorn; Wolfgang Hiddemann
Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications.
Anticancer research 2003;23(6D):4973-6.
2003: Georg Lenz; Alexander Golf; Thomas Rüdiger; Wolfgang Hiddemann; Torsten Haferlach
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.
Blood 2003;102(9):3457-8.
2003: Susanne Schnittger; Martin Weisser; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
Blood 2003;102(8):2746-55.
2003: Torsten Haferlach; Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Gene expression profiling as a tool for the diagnosis of acute leukemias.
Seminars in hematology 2003;40(4):281-95.
2003: Georg Lenz; Ulrich T Hacker; Wolfgang Kern; Andreas Schalhorn; Wolfgang Hiddemann
Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.
Anti-cancer drugs 2003;14(9):731-3.
2003: Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
Blood 2003;102(7):2395-402.
2003: Andrew Grigg; Philippe Solal-Celigny; Peter Hoskin; Kerry Taylor; Andrew McMillan; Roswitha Forstpointner; Pamela Bacon; Jennifer Renwick; Wolfgang Hiddemann
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Leukemia & lymphoma 2003;44(9):1503-8.
2003: Wolfgang Kern; Alexander Kohlmann; Christian Wuchter; Susanne Schnittger; Claudia Schoch; Susanne Mergenthaler; Richard Ratei; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Correlation of protein expression and gene expression in acute leukemia.
Cytometry. Part B, Clinical cytometry 2003;55(1):29-36.
2003: Annika Elsässer; Michael Franzen; Alexander Kohlmann; Martin Weisser; Susanne Schnittger; Claudia Schoch; Venkateshwar A Reddy; Sebastien A Burel; Dong-Er Zhang; Marius Ueffing; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Oncogene 2003;22(36):5646-57.
2003: Michael Fiegl; Christina Rieger; Jan Braess; Torsten Haferlach; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann; Helmut Ostermann
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid.
British journal of haematology 2003;122(4):688-9.
2003: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Molecular characterization of acute leukemias by use of microarray technology.
Genes, chromosomes & cancer 2003;37(4):396-405.
2003: Janki Rangatia; Rajani K Vangala; Sheo M Singh; Abdul A Peer Zada; Annika Elsässer; Alexander Kohlmann; Torsten Haferlach; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
Oncogene 2003;22(30):4760-4.
2003: Mirjam Klaus; Susanne Schnittger; Torsten Haferlach; Martin Dreyling; Wolfgang Hiddemann; Claudia Schoch
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
Cancer genetics and cytogenetics 2003;144(1):36-43.
2003: Wolfgang Kern; Susanne Danhauser-Riedl; Richard Ratei; Susanne Schnittger; Claudia Schoch; Hans-Jochem Kolb; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Haematologica 2003;88(6):646-53.
2003: Karsten Spiekermann; Ksenia Bagrintseva; Ruth Schwab; Karin Schmieja; Wolfgang Hiddemann
Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2140-50.
2003: Wolfgang Hiddemann; Martin Dreyling
Mantle cell lymphoma: therapeutic strategies are different from CLL.
Current treatment options in oncology 2003;4(3):219-26.
2003: Abdul Ali Peer Zada; Sheo M Singh; Venkateshwar A Reddy; Annika Elsässer; Alexander Meisel; Torsten Haferlach; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
Oncogene 2003;22(15):2296-308.
2003: Mathias Gehrmann; Helga Schmetzer; Günther Eissner; Torsten Haferlach; Wolfgang Hiddemann; Gabriele Multhoff
Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells.
Haematologica 2003;88(4):474-6.
2003: Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Martin Dugas; Wolfgang Hiddemann; Torsten Haferlach
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia.
Haematologica 2003;88(3):351-2.
2003: Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
Blood 2003;101(5):2074.
2003: Karsten Spiekermann; Ralf J Dirschinger; Ruth Schwab; Ksenia Bagrintseva; Florian Faber; Christian Buske; Susanne Schnittger; Louise M Kelly; D Gary Gilliland; Wolfgang Hiddemann
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Blood 2003;101(4):1494-504.
2003: Wolfgang Hiddemann; Martin Dreyling; Michael Unterhalt
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Seminars in oncology 2003;30(1 Suppl 2):16-20.
2003: Eric Delabesse; Juan Li; Susanne Schnittger; Wolfgang Hiddemann; Anthony R Green
Absence of SCL mutations in myeloid malignancies.
British journal of haematology 2003;120(3):482-3.
2003: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2003: Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Buchner; Wolfgang Hiddemann
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood 2003;101(1):64-70.
2003: Rajani K Vangala; Marion S Heiss-Neumann; Janki Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Blood 2003;101(1):270-7.
2002: Janki Rangatia; Rajani K Vangala; Nicolai Treiber; Pu Zhang; Hanna S Radomska; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment.
Molecular and cellular biology 2002;22(24):8681-94.
2002: Karsten Spiekermann; Ksenia Bagrintseva; Claudia Schoch; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Blood 2002;100(9):3423-5.
2002: Roswitha Forstpointner; Annette Hänel; Roland Repp; S Hermann; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Deutsche medizinische Wochenschrift (1946) 2002;127(43):2253-8.
2002: Wolfgang Hiddemann
[Clinical studies: an endangered element in optimizing treatment].
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2185.
2002: Michaela Feuring-Buske; Wolfgang Hiddemann; Christian Buske
[Pathogenesis and biology of leukemias].
Der Internist 2002;43(10):1179-89.
2002: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; W D Ludwig; Wolfgang Hiddemann; Claudia Schoch
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia 2002;16(10):2084-91.
2002: Wolfgang Kern; Jan Braess; Marion Kotschofsky; Stefan Samel; Heinz Becker; Wolfgang Hiddemann; Eberhard Schleyer
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Anticancer research 2002;22(5):3099-102.
2002: Claudia Schoch; Torsten Haferlach; Sabina Bursch; Daniela Gerstner; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Genes, chromosomes & cancer 2002;35(1):20-9.
2002: Raymund Buhmann; Christian Kurzeder; Jutta Rehklau; Doreen Westhaus; Sabina Bursch; Wolfgang Hiddemann; Torsten Haferlach; Michael Hallek; Claudia Schoch
CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.
British journal of haematology 2002;118(4):968-75.
2002: Clemens-Martin Wendtner; David M Kofler; Hans D Theiss; Christian Kurzeder; Raymund Buhmann; Carmen Schweighofer; Luca Perabo; Susanne Danhauser-Riedl; Jens Baumert; Wolfgang Hiddemann; Michael Hallek; Hildegard Büning
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.
Blood 2002;100(5):1655-61.
2002: Christina Nickenig; M Schürmann; Tobias Waggershauser; C Tympner; Béatrice Grabein; Wolfgang Hiddemann
[41-year-old patient after liver transplantation with acute abdominal pain].
Der Internist 2002;43(8):995-8.
2002: Gerhard Behre; Venkateshwar A Reddy; Daniel G Tenen; Wolfgang Hiddemann; Abdul Ali Peer Zada; Sheo M Singh
Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia.
Expert opinion on therapeutic targets 2002;6(4):491-5.
2002: Torsten Haferlach; Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
British journal of haematology 2002;118(2):426-31.
2002: Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
Blood 2002;100(3):998-1007.
2002: Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10008-13.
2002: Gerhard Behre; Sheo M Singh; Huaitian Liu; Laura T Bortolin; Maximilian Christopeit; Hanna S Radomska; Janki Rangatia; Wolfgang Hiddemann; Alan D Friedman; Daniel G Tenen
Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.
The Journal of biological chemistry 2002;277(29):26293-9.
2002: Clemens-Martin Wendtner; Sultan Abdel-Rahman; Matthäus Krych; Jens Baumert; Lars H Lindner; Andrea Baur; Wolfgang Hiddemann; Rolf Issels
Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3156-64.
2002: Venkateshwar A Reddy; Atsushi Iwama; Guergana Iotzova; Mathias Schulz; Annika Elsasser; Rajani K Vangala; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions.
Blood 2002;100(2):483-90.
2002: Karsten Spiekermann; Florian Faber; Robert Voswinckel; Wolfgang Hiddemann
The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
Experimental hematology 2002;30(7):767-73.
2002: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Barbara Schmitt; Clemens-Martin Wendtner; Manuela Bergmann; Raymonde Busch; Astrid Franke; Rita Pasold; Rudolf Schlag; Georg Hopfinger; Wolfgang Hiddemann; Bertold Emmerich; Michael Hallek
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Clinical lymphoma 2002;3(1):26-35.
2002: Jörg Bäsecke; Michaela Feuring-Buske; Günter Brittinger; U W Schaefer; Wolfgang Hiddemann; Frank Griesinger
Transcription of AML1 in hematopoietic subfractions of normal adults.
Annals of hematology 2002;81(5):254-7.
2002: Wiebke Hollburg; Wolfgang Hiddemann
[30. Splenomegaly: a symptom with many etiologies].
MMW Fortschritte der Medizin 2002;144(14):I-XII; quiz XIII-XIV.
2002: Helmut R Salih; Gary C Starling; Stephan F Brandl; Renate Pelka-Fleischer; Torsten Haferlach; Wolfgang Hiddemann; Peter Kiener; Volkmar Nuessler
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
British journal of haematology 2002;117(1):76-85.
2002: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Helmut Löffler; Torsten Haferlach; Andrea Schumacher; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Herbert Rasche; Carlo Aul; Axel Heyll; Eva Lengfelder; Wolf-Dieter Ludwig; Georg Maschmeyer; Hartmut Eimermacher; Jochen Karow; Norbert Frickhofen; Wolf-Dietrich Hirschmann; Maria Cristina Sauerland
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: V Heinemann; Wolfgang Hiddemann
[Current treatment strategies in breast carcinoma].
Der Internist 2002;43(3):327-8.
2002: Karsten Spiekermann; Michael Pau; Ruth Schwab; Karin Schmieja; Sabine Franzrahe; Wolfgang Hiddemann
Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Experimental hematology 2002;30(3):262-71.
2002: Oliver J Stoetzer; Alexei Pogrebniak; Renate Pelka-Fleischer; Max Hasmann; Wolfgang Hiddemann; Volkmar Nuessler
Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.
Biochemical pharmacology 2002;63(3):471-83.
2002: Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Eva Lengfelder; Helmut Löffler; Wolfgang Hiddemann; Torsten Haferlach
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):259-63.
2002: Claudia Schoch; Susanne Schnittger; Sabina Bursch; D Gerstner; A Hochhaus; U Berger; R Hehlmann; Wolfgang Hiddemann; Torsten Haferlach
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Leukemia 2002;16(1):53-9.
2001: Michael Schleuning; Wolfgang Hiddemann
[New molecular therapy options in hematology and oncology, exemplified by STI571].
Der Internist 2001;42(12):1591-7.
2001: M Dugas; C Schoch; S Schnittger; T Haferlach; S Danhauser-Riedl; Wolfgang Hiddemann; D Messerer; K Uberla
A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping.
Leukemia 2001;15(12):1805-10.
2001: C Nickenig; N K Lang; C Schoch; Wolfgang Hiddemann; T Haferlach
New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
Annals of hematology 2001;80(11):662-8.
2001: Gabriele Multhoff; Karin Pfister; Mathias Gehrmann; Markus Hantschel; Catharina Gross; M Hafner; Wolfgang Hiddemann
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity.
Cell stress & chaperones 2001;6(4):337-44.
2001: Hans-Joachim Stemmler; K Gutschow; Harald Sommer; M Malekmohammadi; C H Kentenich; Roswitha Forstpointner; S Geuenich; J Bischoff; Wolfgang Hiddemann; Volker Heinemann
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1393-8.
2001: OJ Stötzer; Michael Schleuning; Georg Ledderose; Wolfgang Hiddemann; Hans-Jochem Kolb
[Allogeneic transplantation in malignant lymphoma].
Deutsche medizinische Wochenschrift (1946) 2001;126(39):1062-9.
2001: Peter Koch; Francisco del Valle; Wolfgang E Berdel; Normann Willich; B Reers; Wolfgang Hiddemann; B Grothaus-Pinke; Gabriele Reinartz; Jens Brockmann; A Temmesfeld; R Schmitz; Christian Rübe; Andreas Probst; G Jaenke; H Bodenstein; A Junker; C Pott; Juergen Schultze; Achim Heinecke; Reza Parwaresch; Markus Tiemann
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3874-83.
2001: Peter Koch; Francisco del Valle; Wolfgang E Berdel; Normann Willich; B Reers; Wolfgang Hiddemann; B Grothaus-Pinke; Gabriele Reinartz; Jens Brockmann; A Temmesfeld; R Schmitz; Christian Rübe; Andreas Probst; G Jaenke; H Bodenstein; A Junker; C Pott; Juergen Schultze; Achim Heinecke; Reza Parwaresch; Markus Tiemann
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3861-73.
2001: Clemens-Martin Wendtner; Sultan Abdel-Rahman; Jens Baumert; MH Falk; Matthäus Krych; M Santl; Wolfgang Hiddemann; Rolf Issels
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1609-16.
2001: Rolf Issels; Sultan Abdel-Rahman; Clemens-Martin Wendtner; MH Falk; V Kurze; Hansjörg Sauer; Uelker Aydemir; Wolfgang Hiddemann
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1599-608.
2001: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Helmut Löffler; Claudia Schoch; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; R Andreesen; Leopold Balleisen; Detlef Haase; Hartmut Eimermacher; Carlo Aul; Herbert Rasche; J Uhlig; Andreas Grüneisen; H E Reis; J Hartlapp; Wolf-Dietrich Hirschmann; H J Weh; H J Pielken; Winfried Gassmann; Maria Cristina Sauerland; Achim Heinecke
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: N K Lang; Andreas Schalhorn; Wolfgang Hiddemann
[Pronounced osteoporosis, shrunken stature and blue coloration of sclerae in a 47-year old patient].
Der Internist 2001;42(8):1151-5.
2001: Michael Hallek; Barbara Schmitt; Martin Wilhelm; Raymonde Busch; A Kröber; H P Fostitsch; O Sezer; M Herold; Wolfgang Knauf; Clemens-Martin Wendtner; R Kuse; Mathias Freund; A Franke; F Schriever; Christoph Nerl; Hartmut Döhner; Eckhard Thiel; Wolfgang Hiddemann; Günter Brittinger; Bertold Emmerich
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
British journal of haematology 2001;114(2):342-8.
2001: Jan Braess; Wolfgang Hiddemann
The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.
Leukemia research 2001;25(8):661-3.
2001: Wolfgang Kern; Eberhard Schleyer; Jan Braess; E Wittmer; J Ohnesorge; Michael Unterhalt; B Wörmann; T Büchner; Wolfgang Hiddemann
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Annals of hematology 2001;80(6):334-9.
2001: Jan Braess; G Jahns-Streubel; Claudia Schoch; Detlef Haase; Torsten Haferlach; Michael Fiegl; S Voss; Wolfgang Kern; Eberhard Schleyer; Wolfgang Hiddemann
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: Wolfgang Kern; B Beckert; N Lang; J Stemmler; M Beykirch; J Stein; E Goecke; Tobias Waggershauser; Jan Braess; Andreas Schalhorn; Wolfgang Hiddemann
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):599-603.
2001: Claudia Schoch; Sabina Bursch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia.
Cancer genetics and cytogenetics 2001;127(1):85-8.
2001: Arthur Gerl; Dieter Mühlbayer; G Hansmann; W Mraz; Wolfgang Hiddemann
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.
Cancer 2001;91(7):1297-303.
2001: Thomas Pabst; Beatrice U Mueller; N Harakawa; C Schoch; T Haferlach; Gerhard Behre; Wolfgang Hiddemann; Dong-Er Zhang; Daniel G Tenen
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Nature medicine 2001;7(4):444-51.
2001: Thomas Pabst; Beatrice U Mueller; Pumin Zhang; Hanna S Radomska; Sailaja Narravula; S Schnittger; Gerhard Behre; Wolfgang Hiddemann; Daniel G Tenen
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Nature genetics 2001;27(3):263-70.
2001: G Jahns-Streubel; Jan Braess; Claudia Schoch; C Fonatsch; Detlef Haase; C Binder; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Leukemia 2001;15(3):377-84.
2001: Normann Willich; Gabriele Reinartz; B Reers; Wolfgang Hiddemann; Markus Tiemann; Reza Parwaresch; B Grothaus-Pinke; J Kocik; Peter Koch
Radiotherapy in early stage gastrointestinal lymphoma: results of the German GIT-NHL group.
Annals of hematology 2001;80 Suppl 3():B97-9.
2001: Wolfgang Kern; Jan Braess; S Friedrichsen; Cornelia C Kaufmann; Eberhard Schleyer; Wolfgang Hiddemann
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Journal of cancer research and clinical oncology 2001;127(1):64-8.
2001: Claudia Schoch; Torsten Haferlach; Detlef Haase; Christa Fonatsch; Helmut Löffler; Brigitte Schlegelberger; Peter Staib; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2000: Gabriele Multhoff; Karin Pfister; C Botzler; A Jordan; R Scholz; Helga Schmetzer; R Burgstahler; Wolfgang Hiddemann
Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors.
International journal of cancer. Journal international du cancer 2000;88(5):791-7.
2000: Wolfgang Kern; B Beckert; N Lang; Tobias Waggershauser; Jan Braess; Andreas Schalhorn; Wolfgang Hiddemann
Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
Anticancer research 2000;20(6D):4973-5.
2000: Markus Hantschel; Karin Pfister; A Jordan; R Scholz; Reinhard Andreesen; G Schmitz; Helga Schmetzer; Wolfgang Hiddemann; Gabriele Multhoff
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients.
Cell stress & chaperones 2000;5(5):438-42.
2000: Lienhard Maeck; P Kohaus; Detlef Haase; Wolfgang Hiddemann; F Alves
Differential cellular expression of the human MSH2 protein in normal and myelodysplastic haematopoiesis.
British journal of haematology 2000;111(2):650-5.
2000: Thomas Duell; J Mittermüller; Wolfgang Hiddemann
[Unclear lactate acidosis in a patient with heart failure under long-term diuretic therapy].
Deutsche medizinische Wochenschrift (1946) 2000;125(41):1232-4.
2000: Ulrich Mahlknecht; S Schnittger; Oliver G Ottmann; Claudia Schoch; M Mosebach; Wolfgang Hiddemann; Dieter Hoelzer
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).
Biochimica et biophysica acta 2000;1493(3):342-8.
2000: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Wolf-Dieter Ludwig; Claudia Schoch; Torsten Haferlach; Georg Maschmeyer; Peter Staib; Carlo Aul; G A Heyll; Andreas Grüneisen; Herbert Rasche; J H Eimermacher; Leopold Balleisen; H J Pielken; H E Reis; Frank Griesinger; Albrecht Reichle; Maria Cristina Sauerland; Achim Heinecke
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Wolfgang Kern; Jan Braess; Cornelia C Kaufmann; S Wilde; Eberhard Schleyer; Wolfgang Hiddemann
Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Anticancer research 2000;20(5C):3679-88.
2000: Michaela Feuring-Buske; Michael Kneba; Michael Unterhalt; A Engert; Martin Gramatzki; Erhard Hiller; Lorenz Trümper; Wolfram Brugger; Helmut Ostermann; J Atzpodien; Michael Hallek; E Aulitzky; Wolfgang Hiddemann
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Annals of hematology 2000;79(9):493-500.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Jan Braess; S Voss; G Jahns-Streubel; Claudia Schoch; Torsten Haferlach; Wolfgang Kern; S Keye; Eberhard Schleyer; Wolfgang Hiddemann
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: U Gruber; T Vollmer; Wolfgang Hiddemann
[Palliative psychooncology--demand and methods. Beginning anew at the end?].
Der Internist 2000;41(7):619-26.
2000: Lienhard Maeck; Detlef Haase; Claudia Schoch; Wolfgang Hiddemann; F Alves
Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations.
British journal of haematology 2000;109(4):842-6.
2000: V Heinemann; Wolfgang Hiddemann
[Age factors in cancer therapy].
Der Internist 2000;41(6):544-52.
2000: Martin Schrappe; Alfred Reiter; Wolf-Dieter Ludwig; Jochen Harbott; Martin Zimmermann; Wolfgang Hiddemann; Charlotte Niemeyer; Günter Henze; A Feldges; Felix Zintl; Bernhard Kornhuber; Jörg Ritter; Karl Welte; Helmut Gadner; Hansjörg Riehm
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Blood 2000;95(11):3310-22.
2000: Jan Braess; C Wegendt; G Jahns-Streubel; Wolfgang Kern; S Keye; Michael Unterhalt; Eberhard Schleyer; Wolfgang Hiddemann
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
British journal of haematology 2000;109(2):388-95.
2000: Susanne Schnittger; U Kinkelin; Claudia Schoch; Achim Heinecke; Detlef Haase; Torsten Haferlach; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Frank Griesinger
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia 2000;14(5):796-804.
2000: Michaela Feuring-Buske; Christian Buske; Michael Unterhalt; Wolfgang Hiddemann
Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Annals of hematology 2000;79(4):167-74.
2000: Arthur Gerl; H Sauer; Bernhard Liedl; Wolfgang Hiddemann
[The therapy of testicular tumors 2 decades after the introduction of cisplatin].
Deutsche medizinische Wochenschrift (1946) 2000;125(11):327-34.
2000: B Gahn; Günter Brittinger; G Dölken; Hartmut Döhner; Bertold Emmerich; A Franke; Mathias Freund; C Huber; R Kuse; T Scholten; Wolfgang Hiddemann
Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):169-73.
2000: Normann Willich; Gabriele Reinartz; Eckehard Horst; G Delker; B Reers; Wolfgang Hiddemann; Markus Tiemann; Reza Parwaresch; B Grothaus-Pinke; J Kocik; Peter Koch
Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.
International journal of radiation oncology, biology, physics 2000;46(4):895-901.
2000: Wolfgang Kern; C Schoch; T Haferlach; Jan Braess; Michael Unterhalt; B Wörmann; T Büchner; Wolfgang Hiddemann
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Leukemia 2000;14(2):226-31.
2000: Stefan K Bohlander; V Muschinsky; K Schrader; R Siebert; Brigitte Schlegelberger; Lana Harder; V Schemmel; Christa Fonatsch; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Martin Dreyling
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.
Leukemia 2000;14(1):93-9.
1999: Wolfgang Hiddemann
[Oncology. The path to a pathogenesis-oriented treatment].
Deutsche medizinische Wochenschrift (1946) 1999;124(51-52):1562-5.
1999: G Beyer-Sehlmeyer; Wolfgang Hiddemann; Bernhard Wörmann; Jasmin Bertram
Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1735-42.
1999: Christian Buske; Horst Hannig; E M Schneider; Sabine Blaschke; Gerhard Hunsmann; Walter Bodemer; Wolfgang Hiddemann
Transforming growth factor beta is a growth-inhibitory cytokine of B cell lymphoma in SIV-infected macaques.
AIDS research and human retroviruses 1999;15(16):1477-85.
1999: Wolfgang Hiddemann; W Kern; Claudia Schoch; C Fonatsch; A Heinecke; Bernhard Wörmann; Thomas Büchner
Management of acute myeloid leukemia in elderly patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3569-76.
1999: Thomas M Behr; Bernhard Wörmann; Martin Gramatzki; Joachim Riggert; Stefan Gratz; Martin Béhé; Frank Griesinger; Robert M Sharkey; H J Kolb; Wolfgang Hiddemann; David M Goldenberg; Wolfgang Becker
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3304s-3314s.
1999: Thomas M Behr; A L Salib; Torsten Liersch; Martin Béhé; Christa Angerstein; Rosalyn D Blumenthal; Afshin Fayyazi; Robert M Sharkey; B Ringe; Heinz Becker; Bernhard Wörmann; Wolfgang Hiddemann; David M Goldenberg; Wolfgang Becker
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3232s-3242s.
1999: Michael Peller; Ralf Loeffler; Andrea Baur; P Turner; Sultan Abdel-Rahman; G Futschik; M Santl; Wolfgang Hiddemann; Maximilian Reiser; Rolf Issels
[MRI-controlled regional hyperthermia].
Der Radiologe 1999;39(9):756-63.
1999: W Kern; Claudia Schoch; C Fonatsch; A Heinecke; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
[The therapy of acute myeloid leukemia in patients of advanced age].
Deutsche medizinische Wochenschrift (1946) 1999;124(34-35):1005-14.
1999: Christian Buske; Michaela Feuring-Buske; Michael Unterhalt; Wolfgang Hiddemann
[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies].
Deutsche medizinische Wochenschrift (1946) 1999;124(27):842-7.
1999: Thomas M Behr; S Memtsoudis; Vassilios I Vougioukas; Torsten Liersch; Stefan Gratz; F Schmidt; T Lorf; Stefan Post; Bernhard Wörmann; Wolfgang Hiddemann; B Ringe; Wolfgang Becker
Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Anticancer research 1999;19(4A):2427-32.
1999: Meinolf Karthaus; Dieter Buchheidt; Wolfgang Hiddemann; J Peter Donnelly; Vladimir Krcméry; Xaver Schiel; M Wilhelm; M Helmerking
European Surveillance of Infections in Cancer Patients--ESIC.
Chemotherapy 1999;45(4):237-41.
1999: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Winfried Gassmann; Torsten Haferlach; Christa Fonatsch; Detlef Haase; Claudia Schoch; Dieter K Hossfeld; Eva Lengfelder; Carlo Aul; Axel Heyll; Georg Maschmeyer; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1999: B Gahn; B Wendenburg; C Troff; J Neef; D Grove; Torsten Haferlach; Wolfgang Hiddemann; Bernhard Wörmann
Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level.
British journal of haematology 1999;105(4):955-9.
1999: Stefan Schwartz; G Behre; Volker Heinemann; H Wandt; Elmar Schilling; M Arning; A Trittin; WV Kern; O Boenisch; D Bosse; K Lenz; Wolf-Dieter Ludwig; Wolfgang Hiddemann; W Siegert; Jörg Beyer
Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
Blood 1999;93(11):3654-61.
1999: Claudia Binder; M Schulz; Wolfgang Hiddemann; M Oellerich
Caspase-activation and induction of inducible nitric oxide-synthase during TNF alpha-triggered apoptosis.
Anticancer research 1999;19(3A):1715-20.
1999: S Biethahn; F Alves; S Wilde; Wolfgang Hiddemann; Karsten Spiekermann
Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.
Experimental hematology 1999;27(5):885-94.
1999: Jan Braess; C Wegendt; Michaela Feuring-Buske; Joachim Riggert; Wolfgang Kern; Wolfgang Hiddemann; Eberhard Schleyer
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
British journal of haematology 1999;105(2):388-93.
1999: Christian Buske; Michaela Feuring-Buske; Michael Unterhalt; Wolfgang Hiddemann
Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy.
European journal of cancer (Oxford, England : 1990) 1999;35(4):549-57.
1999: Frank Griesinger; M Pirò-Noack; N Kaib; M Falk; A Renziehausen; C Troff; D Grove; Susanne Schnittger; Thomas Büchner; J Ritter; Wolfgang Hiddemann; Bernhard Wörmann
Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome.
British journal of haematology 1999;105(1):241-55.
1999: Wolfgang Kern; Jan Braess; B Böttger; Cornelia C Kaufmann; Wolfgang Hiddemann; Eberhard Schleyer
Oxaliplatin pharmacokinetics during a four-hour infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):761-5.
1999: Nicola Gökbuget; Renate Arnold; Thomas Büchner; M Freund; Winfried Gassmann; Gerhard Heil; Wolfgang Hiddemann; Helmut Löffler; Thomas Lipp; Wolf-Dieter Ludwig; Georg Maschmeyer; Eckhard Thiel; D Messerer; Dieter Hoelzer
[Treatment of adult acute lymphoblastic leukemia].
Praxis 1999;88(10):407-20.
1999: Michaela Feuring-Buske; Detlef Haase; Christian Buske; Wolfgang Hiddemann; Bernhard Wörmann
Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission.
Leukemia 1999;13(3):386-92.
1999: Dieter Buchheidt; Wolfgang Hiddemann; Xaver Schiel; V Kremery; Meinolf Karthaus; J Peter Donnelly; M Wilhelm; Georg Maschmeyer; H Link; D Adam; M Helmerking
European surveillance of infections and risk factors in cancer patients.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999;18(2):161-3.
1999: Gerald G Wulf; M Unterhalt; Arnd B Buchwald; Dieter Zenker; H Kreuzer; Wolfgang Hiddemann
Hypercoagulability in a patient with hypodysfibrinogenemia: implications for clinical management.
Acta haematologica 1999;101(4):209-12.
1999: Walter Verbeek; Bernhard Wörmann; P Koch; Carlo Aul; H F Hinrichs; Leopold Balleisen; J M Rowe; J Bennett; Detlef Haase; Christa Fonatsch; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1999;125(6):369-74.
1998: Christian Buske; A Engert; R Schnell; V Diehl; Wolfgang Hiddemann
[Monoclonal antibodies in therapy of malignant lymphomas].
Der Internist 1998;39(12):1205-14.
1998: Christian Buske; D Becker; Michaela Feuring-Buske; Horst Hannig; Frank Griesinger; Wolfgang Hiddemann; Bernhard Wörmann
TGF-beta and its receptor complex in leukemic B-cell precursors.
Experimental hematology 1998;26(12):1155-61.
1998: Torsten Haferlach; Helmut Löffler; C Nickenig; L Ramm-Petersen; M Meeder; R Schoch; Brigitte Schlegelberger; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12).
British journal of haematology 1998;103(1):93-9.
1998: Gerald G Wulf; Utz Reichard; B Wormann; Wolfgang Hiddemann
Pneumocystis carinii pneumonia with peripheral nodular infiltrates in a patient with T-acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3476-7.
1998: Christiane Pott; Markus Tiemann; B Linke; M M Ott; M von Hofen; I Bolz; Wolfgang Hiddemann; Reza Parwaresch; Michael Kneba
Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.
Leukemia 1998;12(10):1630-7.
1998: Jan Braess; Mathias Freund; A Hanauske; G Heil; C Kaufmann; Wolfgang Kern; M Schüssler; Wolfgang Hiddemann; Eberhard Schleyer
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Leukemia 1998;12(10):1618-26.
1998: Wolfgang Kern; Jan Braess; A Grote-Metke; H Kuse; R Fuchs; Dieter K Hossfeld; Albrecht Reichle; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Leukemia 1998;12(10):1522-6.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Kuse; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Annals of hematology 1998;77(3):115-22.
1998: Susanne Schnittger; Bernhard Wörmann; Wolfgang Hiddemann; Frank Griesinger
Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors.
Blood 1998;92(5):1728-34.
1998: Horst Hannig; Christian Buske; Kerstin Mätz-Rensing; Gerhard Hunsmann; Wolfgang Hiddemann; Walter Bodemer
Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys.
International journal of cancer. Journal international du cancer 1998;77(5):734-40.
1998: Wolfgang Kern; G Behre; T Rudolf; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Cancer 1998;83(2):291-301.
1998: Wolfgang Hiddemann; Frank Griesinger; Michael Unterhalt
Interferon alfa for the treatment of follicular lymphomas.
The cancer journal from Scientific American 1998;4 Suppl 2():S13-8.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia 1998;12(7):1049-55.
1998: Martin Dreyling; K Schrader; Christa Fonatsch; Brigitte Schlegelberger; Detlef Haase; Claudia Schoch; W Ludwig; Helmut Löffler; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Stefan K Bohlander
MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.
Blood 1998;91(12):4662-7.
1998: Bernhard Wörmann; Christian Buske; Wolfgang Hiddemann
[Systemic therapy of low malignancy non-Hodgkin lymphomas].
Praxis 1998;87(23):806-11.
1998: Gerald G Wulf; G Jahns-Streubel; Bernhard Hemmerlein; K Bonnekessen; Bernhard Wörmann; Wolfgang Hiddemann
Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells.
Annals of hematology 1998;76(6):273-7.
1998: Wolfgang Hiddemann; G Jahns-Streubel; Walter Verbeek; Bernhard Wörmann; Detlef Haase; Claudia Schoch
Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities.
Leukemia research 1998;22 Suppl 1():S23-6.
1998: Bernhard Wörmann; H Meden; Joachim Riggert; Andreas Humpe; Gerald Wulf; B Koch; Michael Köhler; Walther Kuhn; Wolfgang Hiddemann
Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
Anticancer research 1998;18(3C):2237-41.
1998: Wolfgang Hiddemann; Michael Unterhalt; Richard Herrmann; H H Wöltjen; Ernst D Kreuser; Lorenz Trümper; Monika A Reuss-Borst; E Terhardt-Kasten; M Busch; A Neubauer; U Kaiser; R D Hanrath; H Middeke; G Helm; Mathias Freund; H Stein; Markus Tiemann; Reza Parwaresch
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1922-30.
1998: Jasmin Bertram; K Palfner; Wolfgang Hiddemann; Michael Kneba
Overexpression of ribosomal proteins L4 and L5 and the putative alternative elongation factor PTI-1 in the doxorubicin resistant human colon cancer cell line LoVoDxR.
European journal of cancer (Oxford, England : 1990) 1998;34(5):731-6.
1998: Jasmin Bertram; K Palfner; Wolfgang Hiddemann; Michael Kneba
Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression.
Anti-cancer drugs 1998;9(4):311-7.
1998: Bernhard Wörmann; G Wulf; Wolfgang Hiddemann
[Clinical studies in oncology. Relevance, design, ethical considerations].
Medizinische Klinik (Munich, Germany : 1983) 1998;93(3):181-9.
1998: Wolfgang Kern; Jan Braess; H Bertz; Christiane Pott; Eberhard Schleyer; J Finke; Reinhard Rüchel; Wolfgang Hiddemann
Chronic systemic aspergillosis in a patient with acute myeloid leukemia.
Annals of hematology 1998;76(3-4):175-7.
1998: G Behre; H Link; Georg Maschmeyer; P Meyer; U Paaz; M Wilhelm; Wolfgang Hiddemann
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Annals of hematology 1998;76(2):73-80.
1998: Gerald G Wulf; G Jahns-Streubel; R Nobiling; Frank Strutz; Bernhard Hemmerlein; Wolfgang Hiddemann; Bernhard Wörmann
Renin in acute myeloid leukaemia blasts.
British journal of haematology 1998;100(2):335-7.
1998: Torsten Liersch; W Gatzemeier; P Scharnberg; B Jürgens; Bernhard Wörmann; Heinz Becker; HF Rauschecker; Wolfgang Hiddemann; Gerald G Wulf
[Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Langenbecks Archiv für Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 1998;115(Suppl I):277-80.
1997: Dinko Berkovic; Eduard A M Fleer; J Breass; J Pförtner; Eberhard Schleyer; Wolfgang Hiddemann
The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells.
Leukemia 1997;11(12):2079-86.
1997: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1997;11 Suppl 5():S15-21.
1997: Claudia Schoch; Detlef Haase; Christa Fonatsch; Torsten Haferlach; Helmut Löffler; Brigitte Schlegelberger; Dieter K Hossfeld; R Becher; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Claudia Binder; Lutz Binder; D Marx; A Schauer; Wolfgang Hiddemann
Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues.
Anticancer research 1997;17(6D):4299-304.
1997: Bernhard Wörmann; Gerald G Wulf; Frank Griesinger; Wolfgang Hiddemann
[Sensitive detection of disseminated tumor cells--prognostic significance and therapeutic approaches].
Der Internist 1997;38(11):1083-91.
1997: F Alves; Wolfgang Hiddemann
[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy].
Der Internist 1997;38(11):1074-82.
1997: Jan Braess; Kristian Reich; S Willert; F Strutz; Christine Neumann; Wolfgang Hiddemann; Bernhard Wörmann
Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL).
Annals of hematology 1997;75(5-6):227-30.
1997: Torsten Haferlach; M Winkemann; L Ramm-Petersen; M Meeder; R Schoch; K Weber-Matthiesen; Brigitte Schlegelberger; Claudia Schoch; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Helmut Löffler
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
British journal of haematology 1997;99(2):452-9.
1997: Christian Buske; A Twiling; G Gogowski; K Schreiber; Michaela Feuring-Buske; Gerald G Wulf; Wolfgang Hiddemann; Bernhard Wörmann
In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand.
Leukemia 1997;11(11):1862-7.
1997: Martin Dreyling; Lars Bullinger; German Ott; Stephan Stilgenbauer; Hans Konrad Müller-Hermelink; Martin Bentz; Wolfgang Hiddemann; Hartmut Döhner
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Cancer research 1997;57(20):4608-14.
1997: Claudia Binder; Lutz Binder; M Kroemker; Matthias Schulz; Wolfgang Hiddemann
Influence of cycloheximide-mediated downregulation of glucose transport on TNF alpha-induced apoptosis.
Experimental cell research 1997;236(1):223-30.
1997: Christian Buske; Horst Hannig; Wolfgang Hiddemann; Walter Bodemer
Human herpesvirus-8 (HHV-8) DNA associated with anaplastic large cell lymphoma of the B-cell type in an HIV-1-positive patient.
International journal of cancer. Journal international du cancer 1997;73(2):303-4.
1997: Dinko Berkovic; Wolfgang Hiddemann; J Kuduz; Eduard A M Fleer
Expression of two 50 kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1875-80.
1997: Torsten Haferlach; Wolfgang Hiddemann
[Liver involvement in hematologic diseases].
Der Internist 1997;38(10):977-83.
1997: Andreas Humpe; Joachim Riggert; Katalin Vehmeyer; C Troff; Wolfgang Hiddemann; Michael Köhler; Bernhard Wörmann
Comparison of CD34+ cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy.
Transfusion 1997;37(10):1050-7.
1997: S Reiter-Theil; Wolfgang Hiddemann
["Medical Ethics Patient Forum". Results of a model project].
Medizinische Klinik (Munich, Germany : 1983) 1997;92(9):552-7.
1997: G Jahns-Streubel; C Reuter; U Auf der Landwehr; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Blood 1997;90(5):1968-76.
1997: Wolfgang Hiddemann; Georg Maschmeyer; H Link; M Helmerking; D Adam
[Therapy of infections in patients with acute leukemia].
Medizinische Klinik (Munich, Germany : 1983) 1997;92(7):406-9.
1997: Oliver Micke; Ulrich Schäfer; Bernhard Wörmann; Wolfgang Hiddemann; Normann Willich
Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
Anticancer research 1997;17(4B):3007-10.
1997: B Linke; I Bolz; Afshin Fayyazi; M von Hofen; Christiane Pott; Jasmin Bertram; Wolfgang Hiddemann; Michael Kneba
Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes.
Leukemia 1997;11(7):1055-62.
1997: B Gahn; C Schäfer; J Neef; C Troff; Michaela Feuring-Buske; Wolfgang Hiddemann; Bernhard Wörmann
Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia.
Blood 1997;89(12):4275-81.
1997: Dinko Berkovic; S Lüders; M Goeckenjan; Wolfgang Hiddemann; Eduard A M Fleer
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.
Biochemical pharmacology 1997;53(11):1725-33.
1997: V Ivancević; B Wörmann; C Nauck; Dirk Sandrock; Dieter L Munz; Wolfgang Hiddemann; D Emrich
Somatostatin receptor scintigraphy in the staging of lymphomas.
Leukemia & lymphoma 1997;26(1-2):107-14.
1997: Walter Verbeek; Detlef Haase; Claudia Schoch; Wolfgang Hiddemann; Bernhard Wörmann
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
Annals of hematology 1997;74(6):275-7.
1997: Karsten Spiekermann; Bernhard Wörmann; KW Rumpf; Wolfgang Hiddemann
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura.
British journal of haematology 1997;97(3):544-6.
1997: Walter Verbeek; Bernhard Wörmann; P Koch; Carlo Aul; H Hinrichs; Leopold Balleisen; J M Rowe; J Bennett; Thomas Büchner; Wolfgang Hiddemann
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Annals of hematology 1997;74(5):205-8.
1997: Detlef Haase; Michaela Feuring-Buske; C Schäfer; Claudia Schoch; C Troff; B Gahn; Wolfgang Hiddemann; Bernhard Wörmann
Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
Leukemia 1997;11(5):674-9.
1997: Christiane Pott; Wolfgang Hiddemann
Purine analogs in the treatment of chronic lymphocytic leukemia.
Leukemia 1997;11 Suppl 2():S25-8.
1997: Tobias J. Legler; I Fischer; J Dittmann; G Simson; Rainer Lynen; Andreas Humpe; Joachim Riggert; Eberhard Schleyer; Wolfgang Kern; Wolfgang Hiddemann; Michael Köhler
Frequency and causes of refractoriness in multiply transfused patients.
Annals of hematology 1997;74(4):185-9.
1997: Christian Buske; G Gogowski; K Schreiber; Margret Rave-Fränk; Wolfgang Hiddemann; Bernhard Wörmann
Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Experimental hematology 1997;25(4):329-37.
1997: C Reuter; Eberhard Schleyer; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Leukemia 1997;11(4):561-71.
1997: Claus-Henning Köhne; Hansjochen Wilke; Wolfgang Hiddemann; Carsten Bokemeyer; H P Lohrmann; Heinrich Bodenstein; J Preiss; H Rauschecker; H Hill; C Kaufer; J Th Fischer; U Ohl; D Urbanitz; Leopold Balleisen; Hans-Joachim Schmoll
Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
Oncology 1997;54(2):96-101.
1997: Christian Buske; D Becker; Michaela Feuring-Buske; Horst Hannig; G Wulf; C Schäfer; Wolfgang Hiddemann; Bernhard Wörmann
TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors.
Leukemia 1997;11(3):386-92.
1997: Wolfgang Hiddemann; Michael Unterhalt; H Sack
[Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma].
Der Internist 1997;38(2):122-34.
1997: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Michael Zühlsdorf; R Rottmann; G Innig; G Maschmeier; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
Seminars in oncology 1997;24(1):124-31.
1997: Torsten Liersch; Bernhard Wörmann; HF Rauschecker; Cornelia C Kaufmann; Wolfgang Hiddemann; Heinz Becker; W Gatzemeier
[Brief interdisciplinary oncology: a model for ambulatory, multimodal treatment of tumor patients].
Langenbecks Archiv für Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 1997;114():607-9.
1997: Gerald G Wulf; B Jürgens; Torsten Liersch; W Gatzemeier; HF Rauschecker; Christian Buske; Michael Hüfner; Wolfgang Hiddemann; Bernhard Wörmann
Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.
Journal of cancer research and clinical oncology 1997;123(9):514-21.
1997: B Gahn; C Schäfer; J Neef; C Troff; Michaela Feuring-Buske; Wolfgang Hiddemann; Bernhard Wörmann
Detection of trisomy 12 in CD34+ progenitor cells in a patient with B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 2():55-7.
1997: Peter Koch; B Grothaus-Pinke; Wolfgang Hiddemann; Normann Willich; B Reers; Francisco del Valle; H Bodenstein; M Pfreundschuh; E Möller; J Kocik; Reza Parwaresch; Markus Tiemann
Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():85-8.
1997: Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1996: Wolfgang Hiddemann; Georg Maschmeyer; V Runde; H Einsele
[Prevention, diagnosis and therapy of infections in patients with malignant diseases].
Der Internist 1996;37(12):1212-24.
1996: Wolfgang Hiddemann; Dan Longo; Bertrand Coiffier; Richard I Fisher; F Cabanillas; F Cavalli; Lee M Nadler; V T De Vita; T A Lister; J O Armitage
Lymphoma classification--the gap between biology and clinical management is closing.
Blood 1996;88(11):4085-9.
1996: Dinko Berkovic; D Haase; Wolfgang Hiddemann; Eduard A M Fleer
Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Journal of experimental therapeutics & oncology 1996;1(6):368-75.
1996: Jasmin Bertram; K Palfner; Wolfgang Hiddemann; Michael Kneba
Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta.
Anti-cancer drugs 1996;7(8):838-45.
1996: Wolfgang Hiddemann
[Classification of malignant lymphomas--current status and clinical implications].
Therapeutische Umschau. Revue thérapeutique 1996;53(11):816-9.
1996: Dieter Hoelzer; Nicola Gökbuget; R Arnold; Thomas Büchner; Mathias Freund; Winfried Gassmann; Gerhard Heil; Wolfgang Hiddemann; Helmut Löffler; T Lipp; Wolf-Dieter Ludwig; Georg Maschmeyer; Eckhard Thiel; D Messerer
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy].
Der Internist 1996;37(10):994-1007.
1996: Jan Braess; Wolfgang Kern; Michael Unterhalt; Cornelia C Kaufmann; B Ramsauer; M Schüssler; A Kaeser-Fröhlich; Wolfgang Hiddemann; Eberhard Schleyer
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Annals of hematology 1996;73(4):201-4.
1996: Dinko Berkovic; M Goeckenjan; S Lüders; Wolfgang Hiddemann; Eduard A M Fleer
Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells.
Journal of experimental therapeutics & oncology 1996;1(5):302-11.
1996: Gerald G Wulf; G Jahns-Streubel; Frank Strutz; D Basenau; M Hüfner; Christian Buske; Bernhard Wörmann; Wolfgang Hiddemann
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells.
Annals of hematology 1996;73(3):139-41.
1996: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Wolfgang Kern; Thomas Büchner
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: B Gahn; Detlef Haase; Michael Unterhalt; M Drescher; Claudia Schoch; Christa Fonatsch; L W Terstappen; Wolfgang Hiddemann; Thomas Büchner; J M Bennett; Bernhard Wörmann
De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
Leukemia 1996;10(6):946-51.
1996: Michael Unterhalt; R Herrmann; Markus Tiemann; Reza Parwaresch; Harald Stein; L Trümper; M Nahler; Monika A Reuss-Borst; C Tirier; A Neubauer; Mathias Freund; Ernst D Kreuser; H Dietzfelbinger; H Bodenstein; A Engert; Reinhard Stauder; Hartmut Eimermacher; K Landys; Wolfgang Hiddemann
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Leukemia 1996;10(5):836-43.
1996: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1996;10(4):707-12.
1996: Wolfgang Hiddemann; Michael Unterhalt; Bernhard Wörmann
[Therapy of low-grade non-Hodgkin lymphomas].
Praxis 1996;85(12):357-63.
1996: Eduard A M Fleer; Dinko Berkovic; U Grunwald; Wolfgang Hiddemann
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
European journal of cancer (Oxford, England : 1990) 1996;32A(3):506-11.
1996: Jan Braess; J Pförtner; Cornelia C Kaufmann; B Ramsauer; Michael Unterhalt; Wolfgang Hiddemann; Eberhard Schleyer
Detection and determination of the major metabolites of [3H]cytosine arabinoside by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;676(1):131-40.
1996: Claudia Binder; D Marx; Lutz Binder; A Schauer; Wolfgang Hiddemann
Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):129-33.
1996: Wolfgang Hiddemann
[Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy].
Therapeutische Umschau. Revue thérapeutique 1996;53(2):123-32.
1996: Dieter Hoelzer; Wolf-Dieter Ludwig; Eckhard Thiel; Winfried Gassmann; Helmut Löffler; Christa Fonatsch; Harald Rieder; Gerhard Heil; Barbara Heinze; R Arnold; Dieter K Hossfeld; Thomas Büchner; P Koch; Mathias Freund; Wolfgang Hiddemann; Georg Maschmeyer; Axel Heyll; Carlo Aul; T Faak; R Kuse; T H Ittel; M Gramatzki; Helmut Diedrich; K Kolbe; H G Fuhr; K Fischer; C Schadeck-Gressel; A Weiss; I Strohscheer; Bernd Metzner; U Fabry; Nicola Gökbuget; B Völkers; D Messerer; K Uberla
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Blood 1996;87(2):495-508.
1996: Gerald G Wulf; G Edel; B Deneke; U Gottschalk; Wolfgang Hiddemann; Bernhard Wörmann
A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P.
Journal of cancer research and clinical oncology 1996;122(8):476-82.
1995: Claudia Binder; D Marx; R Overhoff; Lutz Binder; A Schauer; Wolfgang Hiddemann
Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(10):1005-10.
1995: K Palfner; Michael Kneba; Wolfgang Hiddemann; Jasmin Bertram
Short technical reports. Quantification of ribozyme-mediated RNA cleavage using silver-stained polyacrylamide gels.
BioTechniques 1995;19(6):926-9.
1995: Wolfgang Hiddemann
Non-Hodgkin's lymphomas--current status of therapy and future perspectives.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2141-5.
1995: B Linke; I Bolz; Christiane Pott; Wolfgang Hiddemann; Michael Kneba
Use of UITma DNA polymerase improves the PCR detection of rearranged immunoglobulin heavy chain CDR3 junctions.
Leukemia 1995;9(12):2133-7.
1995: Michael Kneba; I Bolz; B Linke; Wolfgang Hiddemann
Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis.
Blood 1995;86(10):3930-7.
1995: I Gralow; W F von Hornstein; Eberhard Schleyer; Wolfgang Hiddemann
[Pharmacokinetics of buprenorphine in subcutaneous administration].
Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 1995;30(7):412-6.
1995: Dinko Berkovic; U Grunwald; W Menzel; C Unger; Wolfgang Hiddemann; Eduard A M Fleer
Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells.
European journal of cancer (Oxford, England : 1990) 1995;31A(12):2080-5.
1995: G Jahns-Streubel; C Reuter; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Leukemia 1995;9(11):1857-63.
1995: Detlef Haase; Michaela Feuring-Buske; S Könemann; Christa Fonatsch; C Troff; Walter Verbeek; Arnulf Pekrun; Wolfgang Hiddemann; Bernhard Wörmann
Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations.
Blood 1995;86(8):2906-12.
1995: Walter Verbeek; A Pies; Andreas Humpe; D Grove; C Troff; E Kunze; Wolfgang Hiddemann; Bernhard Wörmann
Mobilization of CD34-positive tumour cells in a patient with testicular mixed germ cell tumour.
British journal of haematology 1995;90(4):947-50.
1995: Michaela Feuring-Buske; Detlef Haase; S Könemann; C Troff; D Grove; Wolfgang Hiddemann; Bernhard Wörmann
Trisomy 4 in 'stem cell-like' leukemic cells of a patient with AML.
Leukemia 1995;9(8):1318-20.
1995: Eberhard Schleyer; J Reinhardt; Michael Unterhalt; Wolfgang Hiddemann
Highly sensitive coupled-column high-performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5-methyltetrahydrofolate in serum and urine.
Journal of chromatography. B, Biomedical applications 1995;669(2):319-30.
1995: Eberhard Schleyer; Jan Braess; B Ramsauer; Michael Unterhalt; C Kaufmann; S Wilde; M Schüssler; Wolfgang Hiddemann
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Leukemia 1995;9(6):1085-90.
1995: I Gralow; W F von Hornstein; Eberhard Schleyer; Wolfgang Hiddemann
[Continuous subcutaneous buprenorphine application in the treatment of cancer pain.].
Schmerz (Berlin, Germany) 1995;9(3):117-23.
1995: B Linke; J Pyttlich; Markus Tiemann; Meinolf Suttorp; Reza Parwaresch; Wolfgang Hiddemann; Michael Kneba
Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias.
Leukemia 1995;9(5):840-7.
1995: Claus-Henning Köhne; Wolfgang Hiddemann; J Schüller; J Weiss; H P Lohrmann; U Schmitz-Hübner; H Bodenstein; C Schöber; Hansjochen Wilke; J Grem
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1201-8.
1995: C Pott-Hoeck; Wolfgang Hiddemann
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):421-33.
1995: K Palfner; Michael Kneba; Wolfgang Hiddemann; Jasmin Bertram
Improvement of hammerhead ribozymes cleaving mdr-1 mRNA.
Biological chemistry Hoppe-Seyler 1995;376(5):289-95.
1995: Michael Kneba; S Eick; Hermann Herbst; Christiane Pott; I Bolz; F Dallenbach; Wolfgang Hiddemann; Harald Stein
Low incidence of mbr bcl-2/JH fusion genes in Hodgkin's disease.
The Journal of pathology 1995;175(4):381-9.
1995: B Ramsauer; Jan Braess; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Hiddemann; Eberhard Schleyer
Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate).
Journal of chromatography. B, Biomedical applications 1995;665(1):183-92.
1995: Jasmin Bertram; K Palfner; M Killian; W Brysch; K H Schlingensiepen; Wolfgang Hiddemann; Michael Kneba
Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes.
Anti-cancer drugs 1995;6(1):124-34.
1995: Wolfgang Hiddemann; T Buchner
Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 4():27-31.
1995: Walter Verbeek; Katalin Vehmeyer; Bernhard Wörmann; Wolfgang Hiddemann
The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1995;121(6):338-42.
1994: Wolfgang Hiddemann; Michael Unterhalt
Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas.
Blood reviews 1994;8(4):225-33.
1994: Bernhard Wörmann; C Reuter; Michael Zühlsdorf; Thomas Büchner; Wolfgang Hiddemann
Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
Seminars in oncology 1994;21(6 Suppl 16):39-43.
1994: Wolfgang Hiddemann; Bernhard Wörmann; C Reuter; Eberhard Schleyer; Michael Zühlsdorf; A Böckmann; Thomas Büchner
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Seminars in oncology 1994;21(6 Suppl 16):33-8.
1994: Alfred Reiter; Martin Schrappe; Wolf-Dieter Ludwig; Wolfgang Hiddemann; S Sauter; Günter Henze; Martin Zimmermann; F Lampert; W Havers; Dietrich Niethammer
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
Blood 1994;84(9):3122-33.
1994: H Link; Georg Maschmeyer; P Meyer; Wolfgang Hiddemann; W Stille; M Helmerking; D Adam
Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.
Annals of hematology 1994;69(5):231-43.
1994: Christian Buske; Wolfgang Hiddemann; Bernhard Wörmann
Proliferation of human leukemic pre-B cells induced by human bone marrow stromal cells and murine fibroblasts.
Cell biology international 1994;18(11):1049-58.
1994: C Binder; Wolfgang Hiddemann
Programmed cell death--many questions still to be answered.
Annals of hematology 1994;69(2):45-55.
1994: Michael Kneba; I Bolz; B Linke; Jasmin Bertram; D Rothaupt; Wolfgang Hiddemann
Characterization of clone-specific rearrangement T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing.
Blood 1994;84(2):574-81.
1994: Georg Maschmeyer; H Link; Wolfgang Hiddemann; P Meyer; M Helmerking; E Eisenmann; J Schmitt; D Adam
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.
Cancer 1994;73(9):2296-304.
1994: Wolfgang Hiddemann; Michael Unterhalt; P Koch; M Nahler; R Herrmann
New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Seminars in hematology 1994;31(2 Suppl 3):32-5.
1994: Wolfgang Hiddemann
[Hematopoietic growth factors. Current status of therapy].
Der Internist 1994;35(4):395-400.
1994: Georg Maschmeyer; H Link; Wolfgang Hiddemann; P Meyer; M Helmerking; E Eisenmann; J Schmitt; D Adam
[Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society].
Medizinische Klinik (Munich, Germany : 1983) 1994;89(3):114-23.
1994: Eberhard Schleyer; A Kamischke; Cornelia C Kaufmann; Michael Unterhalt; Wolfgang Hiddemann
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Leukemia 1994;8(3):435-40.
1994: C Reuter; U Auf der Landwehr; Eberhard Schleyer; Michael Zühlsdorf; C Ameling; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Leukemia 1994;8(2):217-25.
1994: Wolfgang Hiddemann; C Pott-Hoeck
Fludarabine in the management of malignant lymphomas.
Drugs 1994;47 Suppl 6():50-6.
1993: C Schöber; E Papageorgiou; Andreas Harstrick; Carsten Bokemeyer; A Mügge; M Stahl; Hansjochen Wilke; H Poliwoda; Wolfgang Hiddemann; C H Köhne-Wömpner
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Cancer 1993;72(7):2242-7.
1993: Wolfgang Hiddemann; Michael Unterhalt; Christiane Pott; Bernhard Wörmann; D Sandford; Mathias Freund; A Engert; W Gassmann; W Holtkamp; J Seufert
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
Seminars in oncology 1993;20(5 Suppl 7):28-31.
1993: Dieter Hoelzer; Eckhard Thiel; Wolf-Dieter Ludwig; Helmut Löffler; Thomas Büchner; Mathias Freund; Gerhard Heil; Wolfgang Hiddemann; Georg Maschmeyer; B Völkers
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Leukemia 1993;7 Suppl 2():S130-4.
1993: Wolfgang Hiddemann
[Chronic lymphatic leukemia. Current status and perspectives].
Der Internist 1993;34(6):534-41.
1993: Eberhard Schleyer; R Lohmann; C Rolf; A Gralow; Cornelia C Kaufmann; Michael Unterhalt; Wolfgang Hiddemann
Column-switching solid-phase trace-enrichment high-performance liquid chromatographic method for measurement of buprenorphine and norbuprenorphine in human plasma and urine by electrochemical detection.
Journal of chromatography 1993;614(2):275-83.
1993: C R Kusnierz-Glaz; D Normann; R Weinberg; R Fuchs; M Flasshove; Wolfgang Hiddemann; Jürgen van de Loo; Thomas Büchner
Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia.
Hematological oncology 1993;11(2):73-80.
1993: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; K Becker; Leopold Balleisen; Bernd Lathan
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Leukemia & lymphoma 1993;10 Suppl():133-7.
1993: Wolfgang Hiddemann; Frank Griesinger
Preclinical aspects and therapeutic perspectives of acute and chronic leukemias.
Current opinion in oncology 1993;5(1):13-25.
1993: Bernhard Wörmann; M Safford; S Könemann; Thomas Büchner; Wolfgang Hiddemann; L W Terstappen
Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():185-96.
1993: Wolfgang Hiddemann; Jochen Harbott; Wolf-Dieter Ludwig; J Ritter; A Nehmer; A Reiter; A Kolkmeyer; Timothy J Laing; H Riehm
DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():113-21.
1993: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; R Rottmann; Georg Maschmeyer; Wolf-Dieter Ludwig; Michael Zühlsdorf; K Buntkirchen; A Sander; J Aswald
The role of GM-CSF in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():21-4.
1992: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Michael Zühlsdorf; C Rolf; C Reuter; U Kewer; C Uhrmeister; Bernhard Wörmann; Thomas Büchner
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Leukemia 1992;6(12):1273-80.
1992: Thomas Büchner; Wolfgang Hiddemann; U W Schaefer; Helmut Löffler; Georg Maschmeyer; Wolf-Dieter Ludwig; Carlo Aul; Bernd Lathan; Achim Heinecke
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
Leukemia 1992;6 Suppl 4():68-70.
1992: G Behre; Ingolf Schedel; B Nentwig; Bernhard Wörmann; M Essink; Wolfgang Hiddemann
Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.
Antimicrobial agents and chemotherapy 1992;36(10):2139-46.
1992: L W Terstappen; M Safford; Michael Unterhalt; S Könemann; K Zurlutter; K Piechotka; M Drescher; C Aul; Thomas Büchner; Wolfgang Hiddemann
Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
Leukemia 1992;6(10):993-1000.
1992: Gerhard Ehninger; B Proksch; T Wanner; Ulrich Schuler; F W Busch; H Schmidt; Eberhard Schleyer; K Jaschonek; Wolfgang Hiddemann
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Leukemia 1992;6(6):582-7.
1992: Wolfgang Hiddemann; C Ruelfs; C Ottensmeier; H Rückle; E Musch; O Koch; Jürgen van de Loo
Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
Seminars in oncology 1992;19(2 Suppl 3):225-7.
1992: H J Schmoll; C H Köhne-Wömpner; Wolfgang Hiddemann; H Knipp; Hansjochen Wilke; H Bodenstein; Patrick Schöffski; Carsten Bokemeyer; H P Lohrmann; J Preiss
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Seminars in oncology 1992;19(2 Suppl 3):191-6.
1992: H J Schmoll; Wolfgang Hiddemann; Y Rustum; C H Köhne-Wömpner
The emerging role for biomodulation of antineoplastic agents.
Seminars in oncology 1992;19(2 Suppl 3):1-3.
1992: Wolfgang Hiddemann; Michael Kiehl; Michael Zühlsdorf; C Busemann; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Seminars in oncology 1992;19(2 Suppl 4):31-7.
1992: Mathias Freund; Helmut Diedrich; Arnold Ganser; M Gramatzki; Gerhard Heil; Axel Heyll; M Henke; Wolfgang Hiddemann; R Haas; R Kuse
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Cancer 1992;69(3):709-16.
1992: Mathias Freund; S Wunsch-Zeddies; M Schäfers; J Wysk; I Seidel; Wolfgang Hiddemann; A R Hanauske; H Link; H J Schmoll; H Poliwoda
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Annals of hematology 1992;64(2):83-7.
1992: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Georg Maschmeyer; Dieter K Hossfeld; Wolf-Dieter Ludwig; M Nowrousian; Carlo Aul; U W Schaefer
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Leukemia 1992;6 Suppl 2():68-71.
1992: Dieter Hoelzer; Eckhard Thiel; Wolf-Dieter Ludwig; Helmut Löffler; Thomas Büchner; Mathias Freund; Gerhard Heil; Wolfgang Hiddemann; Georg Maschmeyer; B Völkers
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Leukemia 1992;6 Suppl 2():175-7.
1992: L W Terstappen; M Safford; S Könemann; M R Loken; K Zurlutter; Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Leukemia 1992;6(1):70-80.
1991: Bernhard Wörmann; Wolfgang Hiddemann; J Frisch; Michael Zühlsdorf; R Rottmann; A Boeckmann; C Reuter; E A Freire; G Innig; G Schulz
In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Behring Institute Mitteilungen 1991;(90):28-38.
1991: Thomas Büchner; Wolfgang Hiddemann; Monika Koenigsmann; Michael Zühlsdorf; Bernhard Wörmann; A Boeckmann; E A Freire; G Innig; Georg Maschmeyer; Wolf-Dieter Ludwig
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood 1991;78(5):1190-7.
1991: Wolfgang Hiddemann; M E Essink; Wolfgang Fegeler; Michael Zühlsdorf; C Sauerland; Thomas Büchner
Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia.
Cancer 1991;68(1):9-14.
1991: Thomas Büchner; Wolfgang Hiddemann; G Löffler; Winfried Gassmann; Georg Maschmeyer; W Heit; Dieter K Hossfeld; H Weh; Wolf-Dieter Ludwig; Eckhard Thiel
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Seminars in hematology 1991;28(3 Suppl 4):76-9.
1991: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; K Becker; Leopold Balleisen; Bernd Lathan
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Seminars in hematology 1991;28(3 Suppl 4):35-8.
1991: Wolfgang Hiddemann; R Rottmann; Bernhard Wörmann; A Thiel; M Essink; C Ottensmeier; Mathias Freund; Thomas Büchner; Jürgen van de Loo
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Annals of hematology 1991;63(1):1-4.
1991: Wolfgang Hiddemann
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.
Annals of hematology 1991;62(4):119-28.
1991: L W Terstappen; S Könemann; M Safford; M R Loken; K Zurlutter; Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann
Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties.
Leukemia 1991;5(4):315-21.
1991: Monika Koenigsmann; Wolfgang Hiddemann; Thomas Büchner
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML.
Leukemia research 1991;15(1):37-41.
1991: Wolfgang Hiddemann; Michael Unterhalt; P Koch; M Nahler; R Herrmann; Jürgen van de Loo
alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S37-9.
1990: Wolfgang Hiddemann; Michael Unterhalt; P Koch; M Nahler; Jürgen van de Loo
Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Seminars in oncology 1990;17(6 Suppl 10):20-3.
1990: Wolfgang Hiddemann; Thomas Büchner; Gerhard Heil; K Schumacher; Helmut Diedrich; Georg Maschmeyer; Anthony Ho; M Planker; S Gerith-Stolzenburg; R Donhuijsen-Ant
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Leukemia 1990;4(9):637-40.
1990: Wolfgang Hiddemann; Norbert Schmitz; Michael Pfreundschuh; K H Pflüger; J Ollech-Chwoyka; C Tirier; Georg Maschmeyer; H Kirchner; T Wagner; P Koch
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Cancer 1990;66(5):838-43.
1990: Wolfgang Hiddemann; Eberhard Schleyer; C Uhrmeister; Carlo Aul; Georg Maschmeyer; Achim Heinecke; Thomas Büchner
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Cancer treatment reviews 1990;17(2-3):279-85.
1990: G Silling-Engelhardt; Wolfgang Hiddemann
[Paraneoplastic syndromes of the hematopoietic cell system].
Der Internist 1990;31(8):520-5.
1990: W Stenzinger; A Blömker; Wolfgang Hiddemann; Jürgen van de Loo
Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
Blut 1990;61(2-3):55-9.
1990: T Buechner; Wolfgang Hiddemann; Monika Koenigsmann; M Zuehlsdorf; B Woermann; A Boeckmann; E Aguion Freire; G Innig; Georg Maschmeyer; Wolf-Dieter Ludwig
Recombinant human GM-CSF following chemotherapy in high-risk AML.
Bone marrow transplantation 1990;6 Suppl 1():131-4.
1990: M von Eiff; M Essink; Nikolaus Roos; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.
Blut 1990;60(4):242-8.
1990: Wolfgang Hiddemann; W R Martin; C M Sauerland; Achim Heinecke; Thomas Büchner
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Leukemia 1990;4(3):184-8.
1990: Wolfgang Hiddemann; Thomas Büchner
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Blut 1990;60(3):163-71.
1990: T Buechner; Wolfgang Hiddemann
Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.
Blut 1990;60(2):61-7.
1990: Georg Maschmeyer; H Link; Wolfgang Hiddemann; P Meyer; M Helmerking; D Adam
Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy.
Onkologie 1990;13(1):38-42.
1990: M E Essink; Wolfgang Hiddemann; M von Eiff; Thomas Büchner; Jürgen van de Loo
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Haematology and blood transfusion 1990;33():558-9.
1990: M von Eiff; M Essink; Nikolaus Roos; H Schmidt; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
Hepatosplenic candidiasis in acute leukemias.
Haematology and blood transfusion 1990;33():555-7.
1990: C Kusnierz-Glaz; M Reiser; B Hagemeister; Thomas Büchner; Wolfgang Hiddemann; Jürgen van de Loo
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
Haematology and blood transfusion 1990;33():351-6.
1990: C Krehmeier; Michael Zühlsdorf; Thomas Büchner; Wolfgang Hiddemann
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
Haematology and blood transfusion 1990;33():129-32.
1990: Wolfgang Hiddemann; Michael Zühlsdorf; Bernhard Wörmann; Monika Koenigsmann; Thomas Büchner
Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
Leukemia research 1990;14(4):347-52.
1990: Thomas Büchner; Wolfgang Hiddemann; Monika Koenigsmann; M Zuehlsdorf; B Woermann; A Boeckmann; E Aguion Freire; G Innig; Georg Maschmeyer; Wolf-Dieter Ludwig
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse.
Haematology and blood transfusion 1990;33():724-31.
1990: Wolfgang Hiddemann; H C Aul; Georg Maschmeyer; D Urbanitz; Bernd Lathan; A Reichle; H Köppler; R Donhuijsen-Ant; Wolf-Dieter Ludwig; T Grüneisen
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Haematology and blood transfusion 1990;33():604-10.
1990: Mathias Freund; M De Boben; Helmut Diedrich; Arnold Ganser; Gerhard Heil; Axel Heyll; M Henke; Wolfgang Hiddemann; U Knauf; P Koch
Treatment of relapsed acute lymphocytic leukemia in adults.
Haematology and blood transfusion 1990;33():432-6.
1990: Thomas Büchner; Wolfgang Hiddemann; S Blasius; P Koch; Georg Maschmeyer; C Tirier; H Sodomann; Rolf Kuse; Eckhard Thiel; Wolf-Dieter Ludwig
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Haematology and blood transfusion 1990;33():261-6.
1990: Thomas Büchner; Wolfgang Hiddemann; Georg Maschmeyer; W Ludwig; Helmut Löffler; M Nowrousian; Carlo Aul; Achim Heinecke
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):97-9.
1990: Wolfgang Hiddemann; Bernhard Wörmann; D Messerer; R Springefeld; Thomas Büchner
Analysis of the cellular DNA and RNA content in acute leukemias by flow cytometry.
Journal of cancer research and clinical oncology 1990;116(5):507-12.
1989: Eberhard Schleyer; Gerhard Ehninger; Michael Zühlsdorf; B Proksch; Wolfgang Hiddemann
Detection and separation of intracellular 1-beta-D-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography.
Journal of chromatography 1989;497():109-20.
1989: Wolfgang Hiddemann
What's new in malignant tumors in acquired immunodeficiency disorders?
Pathology, research and practice 1989;185(6):930-4.
1989: Wolfgang Hiddemann; D Urbanitz; Peter Preusser; Wolf Achterrath; Thomas Büchner
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hematological oncology 1989;7(4):267-73.
1989: Wolfgang Hiddemann; T Büchner; Jürgen van de Loo
[Principles of relapse therapy in acute myeloid leukemia].
Deutsche medizinische Wochenschrift (1946) 1989;114(15):599-605.
1989: Wolfgang Hiddemann; Carlo Aul; Georg Maschmeyer; Bernd Lathan; H Köppler; R Hoffmann; T Grüneisen; R Donhuijsen-Ant; Wolf-Dieter Ludwig; Leopold Balleisen
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Onkologie 1989;12(1):4-6.
1988: Thomas Büchner; Wolfgang Hiddemann; Michael Zühlsdorf; Monika Koenigsmann; A Böckmann; Jürgen van de Loo; G Schulz
Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk of early death.
Behring Institute Mitteilungen 1988;(83):309-12.
1988: M von Eiff; M Essink; Wolfgang Fegeler; S Schellong; H Schmidt; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
[Clinical course and risk factors in patients with generalized mycoses].
Schweizerische medizinische Wochenschrift 1988;118(16):584-91.
1988: Wolfgang Hiddemann; Thomas Büchner; M Essink; O Koch; W Stenzinger; Jürgen van de Loo
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Onkologie 1988;11(1):10-2.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Mertelsmann; M Planker; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):73-7.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Mertelsmann; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Blood 1987;69(3):744-9.
1987: Georg Maschmeyer; Wolfgang Hiddemann; H Kreutzmann; F Wendt
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Onkologie 1987;10(1):18-21.
1987: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; P Koch; H J Pielken; R Kuse; A Mohr; Georg Maschmeyer; H Kreutzmann; F Wendt
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies].
Onkologie 1987;10(1):14-6.
1987: Wolfgang Hiddemann; H Kreutzmann; R Donhuijsen-Ant; M Planker; F C Wendt; Thomas Büchner
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Onkologie 1987;10(1):11-2.
1987: Thomas Büchner; Wolfgang Hiddemann; D Urbanitz; H Kreutzmann; Georg Maschmeyer; F Wendt; R Kuse; A Mohr; W Gassmann; Helmut Löffler
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Haematology and blood transfusion 1987;30():57-63.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; H J Fuhr; R Donhuijsen-Ant; E Lengfelder; Thomas Büchner
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
Haematology and blood transfusion 1987;30():336-8.
1986: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Onkologie 1986;9(3):144-6.
1986: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; P Koch; H J Pielken; R Kuse; A Mohr; Georg Maschmeyer; H Kreutzmann; F Wendt
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies].
Onkologie 1986;9(2):83-91.
1985: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; H Rühl; Wolf-Dieter Ludwig; J Fischer; H C Aul; H A Vaupel; R Kuse; G Zeile
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(12):1583-9.
1985: Wolfgang Hiddemann; H Kreutzmann; Wolf-Dieter Ludwig; H C Aul; R Donhuijsen-Ant; E Lengfelder; Thomas Büchner
Mitozantrone and high-dose cytarabine in refractory adult acute myeloid leukaemia.
Lancet 1985;2(8453):508-9.
1985: D Urbanitz; H J Pielken; P Koch; Thomas Büchner; Wolfgang Hiddemann; Achim Heinecke; F Wendt; G Maschmeier; J van de Loo
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Onkologie 1985;8(3):157-9.
1984: Thomas Büchner; D Urbanitz; B Emmerich; J Fischer; A Heinecke; Wolfgang Hiddemann; M Pfreundschuh; H Rühl; F Wendt
Long-term remission in acute myelogenous leukaemia.
Lancet 1984;1(8376):571.